<document ID-DOI="10.1016/j.phytochem.2019.112187" ID-ISSN="1873-3700" ID-Zenodo-Dep="8194187" IM.bibliography_approvedBy="diego" IM.illustrations_approvedBy="diego" IM.metadata_approvedBy="felipe" IM.tables_approvedBy="diego" IM.taxonomicNames_approvedBy="felipe" IM.treatments_approvedBy="diego" checkinTime="1690595442190" checkinUser="felipe" docAuthor="Alijevic, Omar &amp; McHugh, Damian &amp; Rufener, Lucien &amp; Mazurov, Anatoly &amp; Hoeng, Julia &amp; Peitsch, Manuel" docDate="2020" docId="FF8B0076FFF1FFC6C353A15AFFF83131" docName="Phytochemistry.170.112187.pdf" docOrigin="Phytochemistry (112187) 170" docSource="http://dx.doi.org/10.1016/j.phytochem.2019.112187" docStyle="DocumentStyle:F36D69FC8B198FBE91029DF9C24697D3.6:Phytochemistry.2020-.journal_article" docStyleId="F36D69FC8B198FBE91029DF9C24697D3" docStyleName="Phytochemistry.2020-.journal_article" docStyleVersion="6" docTitle="An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human α4β2 and α7 nicotinic acetylcholine receptors" docVersion="4" lastPageNumber="20" pageNumber="1" updateTime="1699546633484" updateUser="plazi">
<mods:mods xmlns:mods="http://www.loc.gov/mods/v3">
<mods:titleInfo>
<mods:title>An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human α4β2 and α7 nicotinic acetylcholine receptors</mods:title>
</mods:titleInfo>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>Alijevic, Omar</mods:namePart>
<mods:affiliation>, Damian McHugh &amp; ∗, Lucien Rufener &amp;, Julia Hoeng &amp;, &amp; PMI R&amp;D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland</mods:affiliation>
</mods:name>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>McHugh, Damian</mods:namePart>
</mods:name>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>Rufener, Lucien</mods:namePart>
</mods:name>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>Mazurov, Anatoly</mods:namePart>
</mods:name>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>Hoeng, Julia</mods:namePart>
</mods:name>
<mods:name type="personal">
<mods:role>
<mods:roleTerm>Author</mods:roleTerm>
</mods:role>
<mods:namePart>Peitsch, Manuel</mods:namePart>
</mods:name>
<mods:typeOfResource>text</mods:typeOfResource>
<mods:relatedItem type="host">
<mods:titleInfo>
<mods:title>Phytochemistry</mods:title>
</mods:titleInfo>
<mods:part>
<mods:date>2020</mods:date>
<mods:detail type="series">
<mods:title>112187</mods:title>
</mods:detail>
<mods:detail type="pubDate">
<mods:number>2020-02-29</mods:number>
</mods:detail>
<mods:detail type="volume">
<mods:number>170</mods:number>
</mods:detail>
<mods:extent unit="page">
<mods:start>1</mods:start>
<mods:end>20</mods:end>
</mods:extent>
</mods:part>
</mods:relatedItem>
<mods:location>
<mods:url>http://dx.doi.org/10.1016/j.phytochem.2019.112187</mods:url>
</mods:location>
<mods:classification>journal article</mods:classification>
<mods:identifier type="DOI">10.1016/j.phytochem.2019.112187</mods:identifier>
<mods:identifier type="ISSN">1873-3700</mods:identifier>
<mods:identifier type="Zenodo-Dep">8194187</mods:identifier>
</mods:mods>
<paragraph blockId="0.[100,1280,445,569]" pageId="0" pageNumber="1">
<docTitle pageId="0" pageNumber="1">An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human α4β2 and α7 nicotinic acetylcholine receptors</docTitle>
</paragraph>
<paragraph blockId="0.[100,1191,594,660]" pageId="0" pageNumber="1">
<docAuthor box="[100,274,599,625]" pageId="0" pageNumber="1">Omar Alijevic</docAuthor>
<superScript attach="left" box="[274,285,594,610]" fontSize="7" pageId="0" pageNumber="1">a</superScript>
<docAuthor box="[285,514,599,626]" pageId="0" pageNumber="1">
<docAuthorAffiliation box="[285,514,599,626]" pageId="0" pageNumber="1">, Damian McHugh</docAuthorAffiliation>
</docAuthor>
<superScript attach="left" box="[514,541,594,610]" fontSize="7" pageId="0" pageNumber="1">
a, 
<emphasis bold="true" box="[530,541,594,610]" pageId="0" pageNumber="1">
<docAuthorAffiliation box="[530,541,594,610]" pageId="0" pageNumber="1">∗</docAuthorAffiliation>
</emphasis>
</superScript>
<docAuthor box="[542,749,599,626]" pageId="0" pageNumber="1">, Lucien Rufener</docAuthor>
<superScript attach="left" box="[749,761,594,611]" fontSize="7" pageId="0" pageNumber="1">b</superScript>
<docAuthor box="[760,993,599,626]" pageId="0" pageNumber="1">, Anatoly Mazurov</docAuthor>
<superScript attach="right" box="[994,1005,594,610]" fontSize="7" pageId="0" pageNumber="1">a</superScript>
<docAuthor box="[1004,1173,599,626]" pageId="0" pageNumber="1">
<docAuthorAffiliation box="[1004,1173,599,626]" pageId="0" pageNumber="1">, Julia Hoeng</docAuthorAffiliation>
</docAuthor>
<superScript attach="left" box="[1173,1184,594,610]" fontSize="7" pageId="0" pageNumber="1">a</superScript>
<docAuthor box="[1183,1191,600,626]" pageId="0" pageNumber="1">
<docAuthorAffiliation box="[1183,1191,600,626]" pageId="0" pageNumber="1">,</docAuthorAffiliation>
</docAuthor>
Manuel Peitsch 
<superScript attach="left" box="[291,302,629,645]" fontSize="7" pageId="0" pageNumber="1">a</superScript>
</paragraph>
<paragraph blockId="0.[100,785,679,719]" pageId="0" pageNumber="1">
<superScript attach="left" box="[100,106,679,688]" fontSize="4" pageId="0" pageNumber="1">a</superScript>
<emphasis bold="true" box="[110,785,682,697]" italics="true" pageId="0" pageNumber="1">
<docAuthorAffiliation box="[110,785,682,697]" pageId="0" pageNumber="1">
PMI R&amp;D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, 
<collectingRegion box="[621,693,682,696]" country="Switzerland" name="Neuchatel" pageId="0" pageNumber="1">Neuchâtel</collectingRegion>
, 
<collectingCountry box="[702,785,682,696]" name="Switzerland" pageId="0" pageNumber="1">Switzerland</collectingCountry>
</docAuthorAffiliation>
</emphasis>
<superScript attach="left" box="[100,107,702,712]" fontSize="4" pageId="0" pageNumber="1">b</superScript>
<emphasis bold="true" box="[111,470,705,719]" italics="true" pageId="0" pageNumber="1">
INVENesis Sárl, CH-2000, 
<collectingRegion box="[307,379,705,719]" country="Switzerland" name="Neuchatel" pageId="0" pageNumber="1">Neuchatel</collectingRegion>
, 
<collectingCountry box="[387,470,705,719]" name="Switzerland" pageId="0" pageNumber="1">Switzerland</collectingCountry>
</emphasis>
</paragraph>
<paragraph blockId="0.[100,299,792,809]" box="[100,299,792,809]" pageId="0" pageNumber="1">ARTICLE INFO</paragraph>
<subSection _generate="added" pageId="0" pageNumber="1" type="key_words">
<paragraph blockId="0.[100,174,847,861]" box="[100,174,847,861]" pageId="0" pageNumber="1">
<heading box="[100,174,847,861]" fontSize="36" level="2" pageId="0" pageNumber="1" reason="5">
<emphasis bold="true" box="[100,174,847,861]" italics="true" pageId="0" pageNumber="1">Keywords:</emphasis>
</heading>
</paragraph>
<paragraph blockId="0.[100,236,869,1089]" pageId="0" pageNumber="1">
<taxonomicName _evidence="catalogs" _step="species1" box="[100,236,869,884]" class="Magnoliopsida" family="Solanaceae" genus="Nicotiana" kingdom="Plantae" order="Solanales" pageId="0" pageNumber="1" phylum="Tracheophyta" rank="species" species="tabacum">
<emphasis bold="true" box="[100,236,869,884]" italics="true" pageId="0" pageNumber="1">Nicotiana tabacum</emphasis>
</taxonomicName>
<taxonomicName _evidence="catalogs" _step="family" box="[100,183,893,907]" class="Magnoliopsida" family="Solanaceae" kingdom="Plantae" order="Solanales" pageId="0" pageNumber="1" phylum="Tracheophyta" rank="family">Solanaceae</taxonomicName>
</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,236,915,929]" pageId="0" pageNumber="1">Tobacco alkaloids</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,153,938,952]" pageId="0" pageNumber="1">nAChR</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,141,961,975]" pageId="0" pageNumber="1">α4β2</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,121,984,998]" pageId="0" pageNumber="1">α7</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,163,1007,1021]" pageId="0" pageNumber="1">Nicotine</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,189,1030,1044]" pageId="0" pageNumber="1">Nornicotine</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,178,1052,1066]" pageId="0" pageNumber="1">Anabasine</paragraph>
<paragraph blockId="0.[100,236,869,1089]" box="[100,177,1075,1089]" pageId="0" pageNumber="1">Anatabine</paragraph>
<paragraph blockId="0.[542,686,792,809]" box="[542,686,792,809]" pageId="0" pageNumber="1">ABSTRACT</paragraph>
<paragraph blockId="0.[542,1489,844,1194]" pageId="0" pageNumber="1">
Nicotinic acetylcholine receptor (nAChR) subtype-selective pharmacological profiles of tobacco alkaloids are essential for understanding the physiological effects of tobacco products. In this study, automated electrophysiology was used to functionally characterize the effects of distinct groups of tobacco alkaloids on human α4β2 and α7 nAChRs. We found that, in tobacco alkaloids, pyridine as a hydrogen bond acceptor and a basic nitrogen atom at a distance of 4–7 Å are pharmacophoric elements necessary for molecular recognition by α4β2 and α7 nAChRs with various degrees of selectivity, potency, and efficacy. While four alkaloids—nicotine, nornicotine, anabasine and 
<emphasis bold="true" box="[755,767,999,1015]" italics="true" pageId="0" pageNumber="1">R</emphasis>
-anatabine—potently activated α4β2, they were also weak agonists of α7 nAChRs. Nicotine was the most potent agonist of α4β2, while anabasine elicited the highest activation of α7. None of the tobacco alkaloids enhanced nAChR activity elicited by the endogenous ligand acetylcholine; therefore, none was considered to be a positive allosteric modulator (PAM) of either α4β2 or α7 nAChRs. In contrast, we identified tobacco alkaloids, such as the tryptophan metabolite 6-hydroxykynurenic acid, that decreased the activity of both α4β2 and α7 nAChRs. Our study identified a class of alkaloids with positive and negative effects against human α4β2 and α7 nAChRs. It also revealed human α4β2 to be the principal receptor for sensing the most abundant alkaloids in tobacco leaves.
</paragraph>
</subSection>
<subSection _generate="added" lastPageId="1" lastPageNumber="2" pageId="0" pageNumber="1" type="multiple">
<paragraph blockId="0.[100,258,1290,1309]" box="[100,258,1290,1309]" pageId="0" pageNumber="1">
<heading bold="true" box="[100,258,1290,1309]" fontSize="36" level="1" pageId="0" pageNumber="1" reason="1">
<emphasis bold="true" box="[100,258,1290,1309]" pageId="0" pageNumber="1">1. Introduction</emphasis>
</heading>
</paragraph>
<paragraph blockId="0.[100,771,1346,1756]" lastBlockId="0.[818,1488,1290,1756]" pageId="0" pageNumber="1">
Alkaloids are nitrogen-containing natural organic compounds widely distributed throughout the plant kingdom. The major pyridine alkaloids of tobacco (
<taxonomicName _evidence="catalogs" _step="species1" box="[312,484,1402,1421]" class="Magnoliopsida" family="Solanaceae" genus="Nicotiana" kingdom="Plantae" order="Solanales" pageId="0" pageNumber="1" phylum="Tracheophyta" rank="species" species="tabacum">
<emphasis bold="true" box="[312,484,1402,1421]" italics="true" pageId="0" pageNumber="1">Nicotiana tabacum</emphasis>
</taxonomicName>
L.) have been the subject of particularly intensive exploration. A typical commercial tobacco plant produces alkaloids at levels between 2% and 4% of its total dry weight. Approximately 90% of the total alkaloid content is nicotine (
<bibRefCitation author="Saitoh, F. &amp; Nona, M. &amp; Kawashima, N." pageId="0" pageNumber="1" pagination="477 - 480" refId="ref9989" refString="Saitoh, F., Nona, M., Kawashima, N., 1985. The alkaloid contents of sixty Nicotiana species. Phytochemistry 24, 477 - 480. https: // doi. org / 10.1016 / S 0031 - 9422 (00) 80751 - 7." type="journal article" year="1985">Saitoh et al., 1985</bibRefCitation>
), with the structurally related alkaloids nornicotine, anabasine, and anatabine accounting for almost all of the remaining 10%. Pyridine alkaloids containing pyrrolidine or piperidine rings with a positively charged nitrogen atom serve as a defense against herbivores (
<bibRefCitation author="Steppuhn, A K &amp; Gase &amp; Krock, B. &amp; Halitschke, R. &amp; Baldwin, I. T." box="[108,321,1625,1645]" pageId="0" pageNumber="1" pagination="1074 - 1080" refId="ref10169" refString="Steppuhn, A K Gase, Krock, B., Halitschke, R., Baldwin, I. T., 2004. Nicotine's defensive function in nature. PLoS Biol. 2, 1074 - 1080. https: // doi. org / 10.1371 / journal. pbio. 0020217." type="journal article" year="2004">Steppuhn et al., 2004</bibRefCitation>
). Historically, research on nicotine and other tobacco alkaloids has focused mainly on the insecticidal and pharmacological properties of these compounds (
<bibRefCitation author="Baldwin, I. T. &amp; Halitschke, R. &amp; Kessler, A. &amp; Schittko, U." box="[508,707,1681,1700]" pageId="0" pageNumber="1" pagination="351 - 358" refId="ref7425" refString="Baldwin, I. T., Halitschke, R., Kessler, A., Schittko, U., 2001. Merging molecular and ecological approaches in plant - insect interactions. Curr. Opin. Plant Biol. 4, 351 - 358. https: // doi. org / 10.1016 / S 1369 - 5266 (00) 00184 - 9." type="journal article" year="2001">Baldwin et al., 2001</bibRefCitation>
; 
<bibRefCitation author="Yang, Taoyi &amp; Xiao, Ting &amp; Sun, Qi" pageId="0" pageNumber="1" pagination="611 - 622" refId="ref10492" refString="Yang, Taoyi, Xiao, Ting, Sun, Qi, Wanga, Kewei, 2017. The current agonists and positive allosteric modulators of α 7 nAChR for CNS indications in clinical trials. Acta Pharm. Sin. B 611 - 622. https: // doi. org / 10.1016 / j. apsb. 2017.09.001." type="book chapter" year="2017">Yang et al., 2017</bibRefCitation>
). Although nicotine analogs and other pyridine alkaloids have shown a certain degree of toxicity in clinical studies (Kleinsasser et al., 2003; 
<bibRefCitation author="Mishra, Aseem, Chaturvedi, Pankaj, Datta, Sourav, Sinukumar, Snita, Joshi, Poonam, Garg, Apurva" box="[936,1113,1290,1310]" pageId="0" pageNumber="1" pagination="24 - 31" refId="ref9502" refString="Mishra, Aseem, Chaturvedi, Pankaj, Datta, Sourav, Sinukumar, Snita, Joshi, Poonam, Garg, Apurva, 2015. Harmful effects of nicotine. Indian J. Med. Paediatr. Oncol. 24 - 31. https: // doi. org / 10.4103 / 0971 - 5851.151771." type="book chapter" year="2015">Mishra et al., 2015</bibRefCitation>
; 
<bibRefCitation author="Ji &amp; Lin" box="[1125,1254,1290,1310]" pageId="0" pageNumber="1" pagination="217 - 225" refId="ref8529" refString="Ji, Lin, Melkonian, Goar, Riveles, Karen, Tal, Prue, 2002. Identification of pyridine compounds in cigarette smoke solution that inhibit growth of the chick chorioallantoic membrane. Toxicol. Sci. 69 (1), 217 - 225. https: // doi. org / 10.1093 / toxsci / 69.1.217." type="journal article" year="2002">Ji et al., 2002</bibRefCitation>
; 
<bibRefCitation author="Khan, H. &amp; Patel, S. &amp; Kamal, M. S." box="[1265,1426,1290,1310]" pageId="0" pageNumber="1" pagination="853 - 857" refId="ref8648" refString="Khan, H., Patel, S., Kamal, M. S., 2017. Pharmacological and toxicological profile of harmane-β-carboline alkaloid: friend or foe. Curr. Drug Metabol. 18 (9), 853 - 857. https: // doi. org / 10.2174 / 1389200218666170607100947." type="journal article" year="2017">Khan et al., 2017</bibRefCitation>
), they have demonstrated potential for treating cognitive disorders, depression, anxiety, cancer, and nociceptive and chronic inflammatory pain (
<bibRefCitation author="Holtman, J. R. &amp; Crooks, P. A. &amp; Dwoskin, L. &amp; Wala, E. P." box="[826,1024,1374,1394]" pageId="0" pageNumber="1" pagination="26" refId="ref8297" refString="Holtman, J. R., Crooks, P. A., Dwoskin, L., Wala, E. P., 2010. Nornicotine for the Treatment of Pain. USA Patent 20100216847, August 26." type="journal article" year="2010">Holtman et al., 2010</bibRefCitation>
; 
<bibRefCitation author="Cosford, N. D. &amp; Bleicher, L. &amp; Vernier, J. M. &amp; Chavez-Noriega, L. &amp; Rao, T. S. &amp; Siegel, R. S. &amp; Suto, C. &amp; Washburn, M. &amp; Lloyd, G. K. &amp; McDonald, I. A." box="[1037,1225,1374,1394]" pageId="0" pageNumber="1" pagination="125 - 130" refId="ref7750" refString="Cosford, N. D., Bleicher, L., Vernier, J. M., Chavez-Noriega, L., Rao, T. S., Siegel, R. S., Suto, C., Washburn, M., Lloyd, G. K., McDonald, I. A., 2000. Recombinant human receptors and functional assays in the discovery of altinicline (SIB- 1508 Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharm. Acta Helv. 74 (2 - 3), 125 - 130. https: // doi. org / 10.1016 / S 0165 - 7208 (00) 80008 - 2." type="journal article" year="2000">Cosford et al., 2000</bibRefCitation>
; 
<bibRefCitation author="Rueter, L. E. &amp; Anderson, D. J. &amp; Birggs, C. A. &amp; Donnelly-Roberts, D. L. &amp; Gintant, G. A. &amp; Gopalakrishnan, M. &amp; Lin, N. H." box="[1238,1417,1374,1394]" pageId="0" pageNumber="1" pagination="167 - 182" refId="ref9883" refString="Rueter, L. E., Anderson, D. J., Birggs, C. A., Donnelly-Roberts, D. L., Gintant, G. A., Gopalakrishnan, M., Lin, N. H., et al., 2004. ABT- 089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 10 (2), 167 - 182. https: // doi. org / 10.1111 / j. 1527 - 3458.2004. tb 00011. x." type="journal article" year="2004">Rueter et al., 2004</bibRefCitation>
; 
<bibRefCitation author="Potter, A. &amp; Corwin, J. &amp; Lang, J. &amp; Piasecki, M. &amp; Lenox, R. &amp; Newhouse, P. A." pageId="0" pageNumber="1" pagination="334 - 342" refId="ref9719" refString="Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., Newhouse, P. A., 1999. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT- 418 in Alzheimer's disease. Psychopharmacology 142 (4), 334 - 342. https: // doi. org / 10. 1007 / s 002130050897." type="journal article" year="1999">Potter et al., 1999</bibRefCitation>
; 
<bibRefCitation author="Sapronov, N. S. &amp; Khnychenko, L. K." box="[939,1253,1402,1421]" pageId="0" pageNumber="1" pagination="25 - 27" refId="ref10041" refString="Sapronov, N. S., Khnychenko, L. K., 1982. Pharmacology of the Anabasis aphylla alkaloids anabasine and anabasamine. Farmakologiia i toksikologiia 45 (6), 25 - 27 PMID: 7151996." type="journal article" year="1982">Sapronov and Khnychenko, 1982</bibRefCitation>
; 
<bibRefCitation author="Echeverria, V. &amp; Grizzell, J. A." box="[1266,1481,1402,1421]" pageId="0" pageNumber="1" pagination="1324 - 1333" refId="ref7921" refString="Echeverria, V., Grizzell, J. A., GE, Barreto, 2016. Neuroinflammation: a therapeutic target of cotinine for the treatment of psychiatric disorders? Curr. Pharmaceut. Des. 22, 1324 - 1333. https: // doi. org / 10.2174 / 138161282210160304112511." type="journal article" year="2016">Echeverria et al., 2016</bibRefCitation>
; 
<bibRefCitation author="Owen, R. T. &amp; Serradell, N. &amp; Rosa, E." box="[818,988,1430,1449]" pageId="0" pageNumber="1" pagination="197 - 202" refId="ref9559" refString="Owen, R. T., Serradell, N., Rosa, E., 2008. Ispronicline: nicotinic acetylcholine α 4 β 2 agonist treatment of cognition disorders. Drugs Future 33 (3), 197 - 202. https: // doi. org / 10.1358 / dof. 2008.033.03.1184544." type="journal article" year="2008">Owen et al., 2008</bibRefCitation>
; 
<bibRefCitation author="Tsuzaki, Y. &amp; Ito, A. &amp; Kiuchi, K." box="[1001,1189,1430,1449]" pageId="0" pageNumber="1" refId="ref10312" refString="Tsuzaki, Y., Ito, A., Kiuchi, K., 1994. Lumichrome Derivatives as Inhibitors for Cancer Metastasis., 06279445 Japan Patent." type="book" year="1994">Tsuzaki et al., 1994</bibRefCitation>
).
</paragraph>
<paragraph blockId="0.[818,1488,1290,1756]" pageId="0" pageNumber="1">
Similar to the endogenous neurotransmitter acetylcholine (ACh), nicotine activates ionotropic cholinergic receptors to depolarize neuronal membranes with diverse kinetic, electrophysiological, and pharmacological properties. Human nAChRs are encoded by sixteen genes, including nine that are expressed primarily in the brain (α2–α7 and β2–β4). The other seven, including those that 
<taxonomicName _evidence="document" _step="nonLabeled6" box="[1260,1342,1597,1616]" form="the" pageId="0" pageNumber="1" rank="form">form the</taxonomicName>
muscle-nAChR subtype (α1, β1, γ, δ, and 
<emphasis bold="true" box="[1060,1069,1625,1644]" pageId="0" pageNumber="1">ε</emphasis>
) and α9 and α10, show primarily peripheral expression. The encoded protein subunits assemble in a pentameric structure around a central ion pore (
<bibRefCitation author="Graham, A. &amp; Court, J. A. &amp; CM &amp; Martin-Ruiz, E &amp; Jaros &amp; Perry, R. &amp; Volsen, S. G. &amp; Bose, S." box="[1167,1358,1681,1700]" pageId="0" pageNumber="1" pagination="493 - 507" refId="ref8107" refString="Graham, A., Court, J. A., CM Martin-Ruiz, E Jaros, Perry, R., Volsen, S. G., Bose, S., et al., 2002. Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. Neuroscience 113 (3), 493 - 507. https: // doi. org / 10.1016 / S 0306 - 4522 (02) 00223 - 3." type="journal article" year="2002">Graham et al., 2002</bibRefCitation>
).
</paragraph>
<paragraph blockId="0.[818,1488,1290,1756]" lastBlockId="1.[100,771,159,1043]" lastPageId="1" lastPageNumber="2" pageId="0" pageNumber="1">
Heteromeric α4β2 and homomeric α7 subtypes are the most abundant nicotinic receptors in the human brain. The role of these nAChR subtypes in cognitive processes, mood, pain, and neuroprotection has motivated the discovery of nAChR-selective compounds, some of which have been developed for Alzheimer's disease, attention-deficit/hyperactivity disorder (ADHD), pain, schizophrenia, and major depression (
<bibRefCitation author="Yang, Taoyi &amp; Xiao, Ting &amp; Sun, Qi" box="[218,389,271,290]" pageId="1" pageNumber="2" pagination="611 - 622" refId="ref10492" refString="Yang, Taoyi, Xiao, Ting, Sun, Qi, Wanga, Kewei, 2017. The current agonists and positive allosteric modulators of α 7 nAChR for CNS indications in clinical trials. Acta Pharm. Sin. B 611 - 622. https: // doi. org / 10.1016 / j. apsb. 2017.09.001." type="book chapter" year="2017">Yang et al., 2017</bibRefCitation>
; 
<bibRefCitation author="Echeverria, V." box="[404,568,271,290]" pageId="1" pageNumber="2" pagination="1 - 9" refId="ref7877" refString="Echeverria, V., 2012. Cotinine: beyond that expected, more than a biomarker of tobacco consumption. Front. Pharmacol. 3, 1 - 9. https: // doi. org / 10.3389 / fphar. 2012.00173." type="journal article" year="2012">Echeverria, 2012</bibRefCitation>
; 
<bibRefCitation author="Blum &amp; Angela P. &amp; Lester &amp; Henry A. &amp; Dougherty &amp; Dennis A." box="[583,756,271,290]" pageId="1" pageNumber="2" pagination="13206 - 13211" refId="ref7493" refString="Blum, Angela P., Lester, Henry A., Dougherty, Dennis A., 2010. Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH. Proc. Natl. Acad. Sci. 13206 - 13211. https: // doi. org / 10.1073 / pnas. 1007140107." type="book chapter" year="2010">Blum et al., 2010</bibRefCitation>
). nAChRs containing α3β4 protein units play a role in the well-known deleterious effects of nicotine on respiratory, cardiovascular, and gastrointestinal functions and in its addiction liability (
<bibRefCitation author="Mishra, Aseem, Chaturvedi, Pankaj, Datta, Sourav, Sinukumar, Snita, Joshi, Poonam, Garg, Apurva" box="[587,764,354,374]" pageId="1" pageNumber="2" pagination="24 - 31" refId="ref9502" refString="Mishra, Aseem, Chaturvedi, Pankaj, Datta, Sourav, Sinukumar, Snita, Joshi, Poonam, Garg, Apurva, 2015. Harmful effects of nicotine. Indian J. Med. Paediatr. Oncol. 24 - 31. https: // doi. org / 10.4103 / 0971 - 5851.151771." type="book chapter" year="2015">Mishra et al., 2015</bibRefCitation>
; 
<bibRefCitation author="Grando &amp; Sergei A." box="[100,232,382,401]" pageId="1" pageNumber="2" pagination="419 - 429" refId="ref8189" refString="Grando, Sergei A., 2014. Connections of nicotine to cancer. Nat. Rev. Cancer 419 - 429. https: // doi. org / 10.1038 / nrc 3725." type="book chapter" year="2014">Grando, 2014</bibRefCitation>
). Except for metanicotine, tobacco alkaloids with pharmacophoric elements required for interaction with nAChRs are nonselective (
<bibRefCitation author="Lippiello, P. M. &amp; Bencherif, M. &amp; Caldwell, W. S. &amp; Arrington, S. R. &amp; Fowler, K. W. &amp; Lovette, M. E. &amp; Reeves, L. K." box="[196,395,438,458]" pageId="1" pageNumber="2" pagination="169 - 176" refId="ref9018" refString="Lippiello, P. M., Bencherif, M., Caldwell, W. S., Arrington, S. R., Fowler, K. W., Lovette, M. E., Reeves, L. K., 1996. Metanicotine: a nicotinic agonist with central nervous system selectivity-in vitro and in vivo characterization. Drug Dev. Res. 38, 169 - 176. https: // doi. org / 10.1002 / (SICI) 1098 - 2299 (199607 / 08) 38: 3 / 4 &lt;169 :: AID-DDR 5&gt; 3." type="journal article" year="1996">Lippiello et al., 1996</bibRefCitation>
).
</paragraph>
<paragraph blockId="1.[100,771,159,1043]" pageId="1" pageNumber="2">In the present study, we wanted to examine the therapeutic potential of tobacco by performing an electrophysiological characterization of naturally occurring tobacco alkaloids. We screened 71 tobacco alkaloids in “agonist mode” to explore their standalone properties and in the presence of the endogenous ligand acetylcholine to explore their capacity to act as positive modulators “PAM mode”.</paragraph>
<paragraph blockId="1.[100,771,159,1043]" pageId="1" pageNumber="2">
The electrophysiological screening was performed against human α4β2 and α7 nAChRs with the goal of identifying compounds with activity for these receptor subtypes and against the human α3β4 nAChR deployed as a counter screen. The nAChRs were either stably expressed in Chinese hamster ovary (CHO) cell lines or transiently injected into 
<taxonomicName _evidence="document" _step="document" box="[100,256,773,792]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[100,174,773,792]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
oocytes
</taxonomicName>
for compound validation. Both expression systems have previously been deployed for characterizing nAChR pharmacology since no endogenous ionotropic nicotinic receptors are found (
<bibRefCitation author="Kirsch &amp; Glenn E. &amp; Fedorov &amp; Nikolai B. &amp; Kuryshev &amp; Yuri A. &amp; Liu, Zhiqi &amp; Armstrong &amp; Lucas C. &amp; Orr &amp; Michael S." pageId="1" pageNumber="2" pagination="333 - 344" refId="ref8704" refString="Kirsch, Glenn E., Fedorov, Nikolai B., Kuryshev, Yuri A., Liu, Zhiqi, Armstrong, Lucas C., Orr, Michael S., 2016. Electrophysiology-based assays to detect subtype-selective modulation of human nicotinic acetylcholine receptors. Assay Drug Dev. Technol. 14 (6), 333 - 344. https: // doi. org / 10.1089 / adt. 2015.688." type="journal article" year="2016">Kirsch et al., 2016</bibRefCitation>
; 
<bibRefCitation author="Scheffel, Corinna &amp; Niessen, K. V. &amp; Rappengluck, S. &amp; Wanner, K. T. &amp; Thiermann, H. &amp; Worek, F. &amp; Seeger, T." box="[229,425,856,876]" pageId="1" pageNumber="2" pagination="149 - 156" refId="ref10082" refString="Scheffel, Corinna, Niessen, K. V., Rappengluck, S., Wanner, K. T., Thiermann, H., Worek, F., Seeger, T., 2018. Counteracting desensitization of human α 7 - nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning. Toxicol. Lett. 293, 149 - 156. https: // doi. org / 10.1016 / j. toxlet. 2017.12. 005." type="journal article" year="2018">Scheffel et al., 2018</bibRefCitation>
; 
<bibRefCitation author="Roncarati, Renza &amp; Seredenina, Tamara &amp; Jow, Brian &amp; Jow, Flora &amp; Papini, Silvia &amp; Kramer, Angela &amp; Bothmann, Hendrick &amp; Dunlop, John &amp; Georg, C." box="[440,654,856,876]" pageId="1" pageNumber="2" pagination="3" refId="ref9795" refString="Roncarati, Renza, Seredenina, Tamara, Jow, Brian, Jow, Flora, Papini, Silvia, Kramer, Angela, Bothmann, Hendrick, Dunlop, John, Georg, C., Terstappen, 2008. Functional properties of α 7 nicotinic acetylcholine receptors Co-expressed with RIC- 3 in a stable recombinant CHO-K 1 cell line. Assay Drug Dev. Technol. 6 (2). https: // doi. org / 10. 1089 / adt. 2007.120." type="journal article" year="2008">Roncarati et al., 2008</bibRefCitation>
; Papke and Smith-Maxwell, 2009). In the present study, the majority of tobacco alkaloids showed inhibitory effects against both α4β2 and α7 nAChRs. Importantly, four tobacco alkaloids—namely nicotine, nornicotine, anabasine, and R-anatabine—showed selective agonistic effects against human α4β2 nAChRs, providing insights for designing ligands that selectively interact with a distinct nAChR subtype.
</paragraph>
</subSection>
<subSection _generate="added" lastPageId="11" lastPageNumber="12" pageId="1" pageNumber="2" type="multiple">
<paragraph blockId="1.[100,361,1093,1113]" box="[100,361,1093,1113]" pageId="1" pageNumber="2">
<heading bold="true" box="[100,361,1093,1113]" fontSize="36" level="1" pageId="1" pageNumber="2" reason="1">
<emphasis bold="true" box="[100,361,1093,1113]" pageId="1" pageNumber="2">2. Results and discussion</emphasis>
</heading>
</paragraph>
<paragraph blockId="1.[100,770,1149,1531]" pageId="1" pageNumber="2">
ACh exposure resulted in concentration-dependent activation of human α4β2 and α7 receptors in CHO cells (
<figureCitation box="[547,603,1177,1196]" captionStart="Fig" captionStartId="1.[100,130,1889,1906]" captionTargetBox="[265,1322,1561,1866]" captionTargetId="figure-962@1.[265,1323,1561,1867]" captionTargetPageId="1" captionText="Fig. 1. Representative traces of currents elicited in response to increasing concentrations of ACh. Currents were measured in agonist mode by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a) and human α7 (b) nAChRs. The half-maximal effective concentrations determined by using the Hill equation were 1.02 ± 1.0 μM (a) and 142 ± 16 μM (b) (n = 5–11 cells). Bars indicate (in μM): 0.1 (1), 0.4 (2), 1.2 (3), 3.7 (4), 11.1 (5), 33.3 (6), 100 (7), 300 (8), 900 (9), and 2700 (10). Dotted lines represent zero current." figureDoi="http://doi.org/10.5281/zenodo.8194189" httpUri="https://zenodo.org/record/8194189/files/figure.png" pageId="1" pageNumber="2">Fig. 1</figureCitation>
). The kinetics of ACh-induced transient currents in human α7 receptors were faster than those in human α4β2 receptors, with half-maximal effective concentration (EC 
<subScript attach="left" box="[236,254,1270,1282]" fontSize="5" pageId="1" pageNumber="2">50</subScript>
) values of 142 ± 16 and 1.02 ± 1.0 μM, respectively (
<figureCitation box="[108,164,1289,1308]" captionStart="Fig" captionStartId="1.[100,130,1889,1906]" captionTargetBox="[265,1322,1561,1866]" captionTargetId="figure-962@1.[265,1323,1561,1867]" captionTargetPageId="1" captionText="Fig. 1. Representative traces of currents elicited in response to increasing concentrations of ACh. Currents were measured in agonist mode by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a) and human α7 (b) nAChRs. The half-maximal effective concentrations determined by using the Hill equation were 1.02 ± 1.0 μM (a) and 142 ± 16 μM (b) (n = 5–11 cells). Bars indicate (in μM): 0.1 (1), 0.4 (2), 1.2 (3), 3.7 (4), 11.1 (5), 33.3 (6), 100 (7), 300 (8), 900 (9), and 2700 (10). Dotted lines represent zero current." figureDoi="http://doi.org/10.5281/zenodo.8194189" httpUri="https://zenodo.org/record/8194189/files/figure.png" pageId="1" pageNumber="2">Fig. 1</figureCitation>
). The EC 
<subScript attach="left" box="[255,273,1298,1310]" fontSize="5" pageId="1" pageNumber="2">50</subScript>
values of ACh against human α4β2, α7, and α3β4 nAChRs in 
<taxonomicName _evidence="document" _step="document" box="[217,373,1317,1336]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[217,291,1317,1336]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
oocytes
</taxonomicName>
were 6.16 ± 1.34, 98.71 ± 0.98, and 29.50 ± 5.74 μM, respectively (Supplementary 
<figureCitation box="[551,603,1344,1364]" captionStart="Fig" captionStartId="1.[100,130,1889,1906]" captionTargetBox="[265,1322,1561,1866]" captionTargetId="figure-962@1.[265,1323,1561,1867]" captionTargetPageId="1" captionText="Fig. 1. Representative traces of currents elicited in response to increasing concentrations of ACh. Currents were measured in agonist mode by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a) and human α7 (b) nAChRs. The half-maximal effective concentrations determined by using the Hill equation were 1.02 ± 1.0 μM (a) and 142 ± 16 μM (b) (n = 5–11 cells). Bars indicate (in μM): 0.1 (1), 0.4 (2), 1.2 (3), 3.7 (4), 11.1 (5), 33.3 (6), 100 (7), 300 (8), 900 (9), and 2700 (10). Dotted lines represent zero current." figureDoi="http://doi.org/10.5281/zenodo.8194189" httpUri="https://zenodo.org/record/8194189/files/figure.png" pageId="1" pageNumber="2">Fig. 1</figureCitation>
). Both expression systems (mammalian cells and 
<taxonomicName _evidence="document" _step="document" box="[401,555,1372,1392]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[401,475,1373,1392]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
oocytes
</taxonomicName>
) clearly demonstrated nAChR activity, in agreement with previous studies (
<bibRefCitation author="Buisson, B. &amp; Gopalakrishnan, M. &amp; Arneric, S. P. &amp; Sullivan, J. P. &amp; Bertrand, D." pageId="1" pageNumber="2" pagination="24" refId="ref7617" refString="Buisson, B., Gopalakrishnan, M., Arneric, S. P., Sullivan, J. P., Bertrand, D., 1996. Human α 4 β 2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J. Neurosci. 16, 24. https: // doi. org / 10.1523 / JNEUROSCI. 16 - 24 - 07880.1996." type="journal article" year="1996">Buisson et al., 1996</bibRefCitation>
, 
<bibRefCitation author="Papke, R. L. &amp; Porter Papke, J. K." box="[160,380,1428,1448]" pageId="1" pageNumber="2" pagination="61" refId="ref9616" refString="Papke, R. L., Porter Papke, J. K., 2002. Comparative pharmacology of rat and human α 7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 49, 61. https: // doi. org / 10.1038 / sj. bjp. 0704833." type="journal article" year="2002">Papke and Porter, 2002</bibRefCitation>
; 
<bibRefCitation author="Tang, Jing-shu &amp; Xie, Bing-xue &amp; Bian, Xi-ling &amp; Xue, Yu &amp; Wei, Ning-ning &amp; Zhou, Jing-heng &amp; Yu-chen &amp; Hao, Li" box="[392,550,1428,1448]" pageId="1" pageNumber="2" pagination="800 - 812" refId="ref10224" refString="Tang, Jing-shu, Xie, Bing-xue, Bian, Xi-ling, Xue, Yu, Wei, Ning-ning, Zhou, Jing-heng, Yu-chen, Hao, Li, Gang, Zhang, Liang-ren, Wang, Ke-wei, 2015. Identification and in vitro pharmacological characterization of a novel and selective α 7 nicotinic acetylcholine receptor agonist, Br-IQ 17 B. Acta Pharmacol. Sin. 36, 800 - 812. https: // doi. org / 10.1038 / aps. 2015.9." type="journal article" year="2015">Tang et al., 2015</bibRefCitation>
; 
<bibRefCitation author="Hamouda &amp; Ayman K. &amp; Deba, Farah &amp; Wang, Ze-Jun &amp; Cohen &amp; Jonathan B." box="[561,764,1428,1448]" pageId="1" pageNumber="2" pagination="575 - 584" refId="ref8224" refString="Hamouda, Ayman K., Deba, Farah, Wang, Ze-Jun, Cohen, Jonathan B., 2016. Photolabeling a nicotinic acetylcholine receptor (nAChR) with an (α 4) 3 (β 2) 2 nAChR-selective positive allosteric modulator. Mol. Pharmacol. 89 (5), 575 - 584. https: // doi. org / 10.1124 / mol. 116.103341." type="journal article" year="2016">Hamouda et al., 2016</bibRefCitation>
; 
<bibRefCitation author="Hone &amp; Arik J. &amp; Michael McIntosh, J." box="[100,266,1456,1475]" pageId="1" pageNumber="2" pagination="37 - 52" refId="ref8339" refString="Hone, Arik J., Michael McIntosh, J., Rueda-Ruzafa, Lola, Passas, Juan, de Castro-Guerin, Cristina, Blazq, Jesus, Gonzalez-Enguita, Carmen, Albillos, Almudena, 2017. Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells. J. Neurochem. 140 (1), 37 - 52. https: // doi. org / 10.1111 / jnc. 13883." type="journal article" year="2017">Hone et al., 2017</bibRefCitation>
).
</paragraph>
<paragraph blockId="1.[100,770,1149,1531]" lastBlockId="1.[818,1487,159,206]" pageId="1" pageNumber="2">
The alkaloids were categorized into four groups according to the established pharmacophoric elements required for interaction with the α7 (
<bibRefCitation author="Mazurov, A. A. &amp; Speake, J. D. &amp; Yohannes, D." box="[857,1053,159,179]" pageId="1" pageNumber="2" pagination="7943 - 7961" refId="ref9231" refString="Mazurov, A. A., Speake, J. D., Yohannes, D., 2011. Discovery and development of α 7 nicotinic acetylcholine receptor modulators. J. Med. Chem. 54, 7943 - 7961. https: // doi. org / 10.1021 / jm 2007672." type="journal article" year="2011">Mazurov et al., 2011</bibRefCitation>
) and α4β2 (
<bibRefCitation author="Mazurov, A. A. &amp; Miao, L. &amp; Bhatti, B. S. &amp; Strachan, J. P. &amp; Akireddy, S. &amp; Murthy, S. &amp; Kombo, D." box="[1172,1367,159,179]" pageId="1" pageNumber="2" pagination="9181 - 9194" refId="ref9287" refString="Mazurov, A. A., Miao, L., Bhatti, B. S., Strachan, J. P., Akireddy, S., Murthy, S., Kombo, D., et al., 2012. Discovery of 3 - (5 - chloro- 2 - furoyl) - 3,7 - diazabicyclo [3.3.0] octane (TC- 6683, AZD 1446), a novel highly selective α 4 β 2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. J. Med. Chem. 55, 9181 - 9194. https: // doi. org / 10.1021 / jm 3006542." type="journal article" year="2012">Mazurov et al., 2012</bibRefCitation>
) subtypes of nAChRs (
<tableCitation box="[907,978,187,206]" captionStart="Table 1" captionStartId="2.[100,150,161,177]" captionTargetPageId="2" captionText="Table 1 Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, agonist induced current at 3.7 μM; I33.3μM, agonist induced current at 33.3 μM." pageId="1" pageNumber="2">Table 1</tableCitation>
):
</paragraph>
<paragraph blockId="1.[819,1487,243,430]" pageId="1" pageNumber="2">A. Compounds containing pyridine as a hydrogen bond acceptor and a basic nitrogen atom, both of which are pharmacophoric elements necessary for molecular recognition by nAChRs;</paragraph>
<paragraph blockId="1.[819,1487,243,430]" pageId="1" pageNumber="2">B. Compounds containing pyridine and an amide moiety replacing a basic nitrogen atom;</paragraph>
<paragraph blockId="1.[819,1487,243,430]" box="[821,1117,382,401]" pageId="1" pageNumber="2">C. Heteroaromatic compounds;</paragraph>
<paragraph blockId="1.[819,1487,243,430]" box="[819,1103,410,430]" pageId="1" pageNumber="2">D. Miscellaneous compounds.</paragraph>
<paragraph blockId="1.[818,1488,466,1517]" pageId="1" pageNumber="2">
The mechanisms of action of the tobacco alkaloids were tested in “agonist mode” and/or in “PAM mode” (
<figureCitation box="[1208,1263,494,513]" captionStart="Fig" captionStartId="8.[100,130,738,755]" captionTargetBox="[191,1397,165,712]" captionTargetId="figure-959@8.[189,1399,152,715]" captionTargetPageId="8" captionText="Fig. 2. Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator." figureDoi="http://doi.org/10.5281/zenodo.8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="1" pageNumber="2">Fig. 2</figureCitation>
). The compounds were tested in CHO cell lines stably expressing human α4β2 or α7 nAChRs by using an automated patch-clamp electrophysiology-based assay (see sections 4.3). In parallel, the most active alkaloids—that is, those in group A—were validated by a two-electrode voltage-clamp electrophysiological assay in 
<taxonomicName _evidence="document" _step="document" box="[1030,1180,634,653]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[1030,1104,634,653]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
oocytes
</taxonomicName>
expressing human α4β2 and α7 nAChRs and then counterscreened against α3β4 nAChRs (see section 4.5).
</paragraph>
<paragraph blockId="1.[818,1488,466,1517]" pageId="1" pageNumber="2">
To evaluate the agonistic effect, cells were exposed at 2-min intervals to a single alkaloid concentration (3.7 and/or 33.3 μM) for approximately 40–80 ms by using the integrated perfusion feature of the automated patch-clamp system (Patchliner, Nanion Technologies). At the end of the protocol, maximal activation of nAChR current was elicited by exposing the CHO cells to the 
<subScript attach="left" box="[1176,1232,857,878]" fontSize="5" pageId="1" pageNumber="2">ECmax</subScript>
ACh corresponding to 33.3 and 900 μM for human α4β2 and α7 nAChRs, respectively. If the agonistic effect of an alkaloid exceeded ~10% of the maximum response induced by the ACh signal, additional concentration–response experiments were performed for potency assessment. A similar strategy was used to assess the agonistic effect of the alkaloids from group A in 
<taxonomicName _evidence="document" _step="document" box="[818,970,1024,1043]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[818,892,1024,1043]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
oocytes
</taxonomicName>
experiments (Supplementary 
<figureCitation box="[1261,1317,1024,1043]" captionStart="Fig" captionStartId="8.[100,130,738,755]" captionTargetBox="[191,1397,165,712]" captionTargetId="figure-959@8.[189,1399,152,715]" captionTargetPageId="8" captionText="Fig. 2. Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator." figureDoi="http://doi.org/10.5281/zenodo.8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="1" pageNumber="2">Fig. 2</figureCitation>
and section 4.5). The electrophysiological patch-clamp and two-electrode voltage-clamp endpoint data of the agonistic effects of the tobacco alkaloids are presented in 
<tableCitation box="[907,985,1107,1127]" captionStart="Table 1" captionStartId="2.[100,150,161,177]" captionTargetPageId="2" captionText="Table 1 Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, agonist induced current at 3.7 μM; I33.3μM, agonist induced current at 33.3 μM." pageId="1" pageNumber="2">Tables 1</tableCitation>
and 
<tableCitation box="[1030,1042,1108,1127]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="1" pageNumber="2">2</tableCitation>
, respectively. The electrophysiological data are summarized as a heatmap in 
<tableCitation box="[1098,1169,1135,1155]" captionStart="Table 4" captionStartId="17.[100,150,161,177]" captionTargetId="graphics-1968@17.[627,1110,445,1284]" captionTargetPageId="17" captionText="Table 4 Heatmap of the tobacco alkaloids tested at 33.3 μM on human α7, α4β2, and α3β4 nAChRs stably expressed in CHO cells or transiently injected in Xenopus oocytes. The two-graded color scale between blue (weak) and red (potent) is differentially set to indicate potency (EC50, red ≤ 10 μM) and agonistic effect (IAGO, red ≥ 50% response relative to Imax ACh). The three-graded color scale between black (inhibition), green (no effect), and red (potentiation) is set for IAGO+ACh as follow; black ≥ 80% decrease relative to EC20 ACh; red ≥ 2x-fold increase relative to EC20 ACh. EC50, half-maximal effective concentration; h, human; nAChR, nicotinic acetylcholine receptors; AGO, agonist; IAGO, response of the agonist; IAGO+ACh, response of the agonist in the presence of the ACh EC20." pageId="1" pageNumber="2">Table 4</tableCitation>
.
</paragraph>
<paragraph blockId="1.[818,1488,466,1517]" pageId="1" pageNumber="2">
Nicotine (
<emphasis bold="true" box="[945,957,1163,1182]" pageId="1" pageNumber="2">1</emphasis>
) was found to be the most potent α4β2 agonist among the tested alkaloids, with 70 times greater potency than that against α7 (EC 
<subScript attach="left" box="[851,869,1228,1240]" fontSize="5" pageId="1" pageNumber="2">50</subScript>
: 0.79 ± 0.16 and 57 ± 13.7 μM, respectively) (
<bibRefCitation author="Wu, Jie &amp; Liu &amp; Qiang, Yu &amp; Kewei, Hu &amp; Jun, Kuo &amp; Yen-Ping, Segerberg &amp; Marsha, Paul A &amp; St John, J" box="[1336,1481,1219,1239]" pageId="1" pageNumber="2" pagination="103 - 118" refId="ref10418" refString="Wu, Jie, Liu, Qiang, Yu, Kewei, Hu, Jun, Kuo, Yen-Ping, Segerberg, Marsha, Paul A St John, J Lukas, Ronald, 2006. Roles of nicotinic acetylcholine receptor βsubunits in function of human α 4 - containing nicotinic receptors. J. Physiol. 103 - 118. https: // doi. org / 10.1113 / jphysiol. 2006.114645." type="book chapter" year="2006">Wu et al., 2006</bibRefCitation>
; 
<bibRefCitation author="Briggs, C. A. &amp; Mckenna, D. G." box="[818,997,1247,1266]" pageId="1" pageNumber="2" pagination="583 - 590" refId="ref7561" refString="Briggs, C. A., Mckenna, D. G., Piattina-kaplan, M., 1995. Human α 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 583 - 590. https: // doi. org / 10.1016 / 0028 - 3908 (95) 00028 - 5." type="book chapter" year="1995">Briggs et al., 1995</bibRefCitation>
). However, it showed similar efficacy for both receptors (
<subScript attach="left" box="[898,936,1275,1296]" fontSize="5" pageId="1" pageNumber="2">Imax</subScript>
values relative to the response of 
<subScript attach="left" box="[1256,1312,1275,1296]" fontSize="5" pageId="1" pageNumber="2">ECmax</subScript>
ACh for α4β2 and α7 were 159% ± 17% and 150% ± 90%, respectively).
</paragraph>
<paragraph blockId="1.[818,1488,466,1517]" lastBlockId="7.[100,770,1820,1979]" lastPageId="7" lastPageNumber="8" pageId="1" pageNumber="2">
The same trend was observed in the results obtained with 
<taxonomicName _evidence="catalogs" _step="genera" box="[1413,1487,1331,1350]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="2" phylum="Arthropoda" rank="genus">
<emphasis bold="true" box="[1413,1487,1331,1350]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
</taxonomicName>
<taxonomicName _authorityPlausibility="0.5859363" _evidence="document" _step="nonLabeled1" authority=": Nicotine" authorityName="Nicotine" box="[818,983,1359,1378]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="2" phylum="Arthropoda" rank="species" species="oocytes">oocytes: Nicotine</taxonomicName>
(
<emphasis bold="true" box="[1002,1014,1359,1378]" pageId="1" pageNumber="2">1</emphasis>
) was the most potent α4β2 agonist among the tested alkaloids, with 60 and 80 times greater potency than for α7 and α3β4 (EC 
<subScript attach="left" box="[911,929,1423,1435]" fontSize="5" pageId="1" pageNumber="2">50</subScript>
: 0.45 ± 3.9, 27.08 ± 3.2, and 36.60 ± 3.2 μM, respectively). In contrast to the patch-clamp results, the results of the 
<taxonomicName _evidence="catalogs" _step="genera" box="[1413,1487,1442,1461]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="1" pageNumber="2" phylum="Arthropoda" rank="genus">
<emphasis bold="true" box="[1413,1487,1442,1461]" italics="true" pageId="1" pageNumber="2">Xenopus</emphasis>
</taxonomicName>
oocyte experiments suggest that nicotine has a lower efficacy against α4β2 and α7, while still behaving as a full agonist when applied to α3β4 (
<subScript attach="left" box="[171,209,1820,1841]" fontSize="5" pageId="7" pageNumber="8">Imax</subScript>
: 17% ± 4%, 57% ± 13%, and 256% ± 89%, respectively).
</paragraph>
<caption ID-DOI="http://doi.org/10.5281/zenodo.8194189" ID-Zenodo-Dep="8194189" httpUri="https://zenodo.org/record/8194189/files/figure.png" pageId="1" pageNumber="2" startId="1.[100,130,1889,1906]" targetBox="[265,1322,1561,1866]" targetPageId="1" targetType="figure">
<paragraph blockId="1.[100,1487,1889,1983]" pageId="1" pageNumber="2">
<emphasis bold="true" box="[100,157,1889,1906]" pageId="1" pageNumber="2">Fig. 1.</emphasis>
Representative traces of currents elicited in response to increasing concentrations of ACh. Currents were measured in agonist mode by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a) and human α7 (b) nAChRs. The half-maximal effective concentrations determined by using the Hill equation were 1.02 ± 1.0 μM (a) and 142 ± 16 μM (b) (n = 5–11 cells). Bars indicate (in μM): 0.1 (1), 0.4 (2), 1.2 (3), 3.7 (4), 11.1 (5), 33.3 (6), 100 (7), 300 (8), 900 (9), and 2700 (10). Dotted lines represent zero current.
</paragraph>
</caption>
<caption pageId="2" pageNumber="3" startId="2.[100,150,161,177]" targetBox="[69,1494,313,1903]" targetPageId="2" targetType="table">
<paragraph blockId="2.[100,1487,161,280]" box="[100,168,161,178]" pageId="2" pageNumber="3">
<emphasis bold="true" box="[100,168,161,178]" pageId="2" pageNumber="3">Table 1</emphasis>
</paragraph>
<paragraph blockId="2.[100,1487,161,280]" pageId="2" pageNumber="3">
Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC 
<subScript attach="left" box="[322,338,244,256]" fontSize="5" pageId="2" pageNumber="3">50</subScript>
, half-maximal effective concentration; 
<subScript attach="right" box="[673,707,238,257]" fontSize="5" pageId="2" pageNumber="3">Imax</subScript>
, maximal response of the agonist; I 
<subScript attach="left" box="[1010,1051,244,256]" fontSize="5" pageId="2" pageNumber="3">3.7μM</subScript>
, agonist induced current at 3.7 μM; I 
<subScript attach="left" box="[1366,1415,244,256]" fontSize="5" pageId="2" pageNumber="3">33.3μM</subScript>
, agonist induced current at 33.3 μM.
</paragraph>
</caption>
<paragraph blockId="2.[1286,1487,1918,1937]" box="[1286,1487,1918,1937]" pageId="2" pageNumber="3">
<tableNote box="[1286,1487,1918,1937]" pageId="2" pageNumber="3">
(
<emphasis bold="true" box="[1293,1480,1919,1936]" italics="true" pageId="2" pageNumber="3">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="3.[100,266,160,178]" box="[100,266,160,178]" pageId="3" pageNumber="4">
<emphasis bold="true" box="[100,168,161,178]" pageId="3" pageNumber="4">Table 1</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="3" pageNumber="4">continued</emphasis>
)
</paragraph>
<paragraph blockId="3.[1286,1487,1539,1557]" box="[1286,1487,1539,1557]" pageId="3" pageNumber="4">
<tableNote box="[1286,1487,1539,1557]" pageId="3" pageNumber="4">
(
<emphasis bold="true" box="[1293,1480,1540,1557]" italics="true" pageId="3" pageNumber="4">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="4.[100,266,160,178]" box="[100,266,160,178]" pageId="4" pageNumber="5">
<emphasis bold="true" box="[100,168,161,178]" pageId="4" pageNumber="5">Table 1</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="4" pageNumber="5">continued</emphasis>
)
</paragraph>
<paragraph blockId="4.[1286,1487,1957,1975]" box="[1286,1487,1957,1975]" pageId="4" pageNumber="5">
<tableNote box="[1286,1487,1957,1975]" pageId="4" pageNumber="5">
(
<emphasis bold="true" box="[1293,1480,1958,1975]" italics="true" pageId="4" pageNumber="5">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="5.[100,266,160,178]" box="[100,266,160,178]" pageId="5" pageNumber="6">
<emphasis bold="true" box="[100,168,161,178]" pageId="5" pageNumber="6">Table 1</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="5" pageNumber="6">continued</emphasis>
)
</paragraph>
<paragraph blockId="5.[1286,1487,1826,1845]" box="[1286,1487,1826,1845]" pageId="5" pageNumber="6">
<tableNote box="[1286,1487,1826,1845]" pageId="5" pageNumber="6">
(
<emphasis bold="true" box="[1293,1480,1827,1844]" italics="true" pageId="5" pageNumber="6">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="6.[100,266,160,178]" box="[100,266,160,178]" pageId="6" pageNumber="7">
<emphasis bold="true" box="[100,168,161,178]" pageId="6" pageNumber="7">Table 1</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="6" pageNumber="7">continued</emphasis>
)
</paragraph>
<paragraph blockId="6.[1286,1487,930,948]" box="[1286,1487,930,948]" pageId="6" pageNumber="7">
<tableNote box="[1286,1487,930,948]" pageId="6" pageNumber="7">
(
<emphasis bold="true" box="[1293,1480,931,948]" italics="true" pageId="6" pageNumber="7">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="7.[100,266,160,178]" box="[100,266,160,178]" pageId="7" pageNumber="8">
<emphasis bold="true" box="[100,168,161,178]" pageId="7" pageNumber="8">Table 1</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="7" pageNumber="8">continued</emphasis>
)
</paragraph>
<paragraph blockId="7.[100,770,1820,1979]" lastBlockId="8.[100,771,903,1982]" lastPageId="8" lastPageNumber="9" pageId="7" pageNumber="8">
Alkaloids 
<emphasis bold="true" box="[230,278,1875,1895]" pageId="7" pageNumber="8">7–11</emphasis>
, which are structurally closely related to nicotine, exhibit structure–activity relationships similar to those of nicotine's synthetic analogue's, according to their affinity binding data for the rat brain agonist site (
<bibRefCitation author="Lin, N. H. &amp; Carrera, C. M. &amp; Anderson, D. J." box="[291,449,1959,1979]" pageId="7" pageNumber="8" pagination="3542 - 3553" refId="ref8855" refString="Lin, N. H., Carrera, C. M., Anderson, D. J., 1994. Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands. J. Med. Chem. 37, 3542 - 3553. https: // doi. org / 10.1021 / jm 00047 a 012." type="journal article" year="1994">Lin et al., 1994</bibRefCitation>
) as well as the ability of these alkaloids to stimulate dopamine release from striatal synaptosomes (
<bibRefCitation author="Lippiello, P. M. &amp; Caldwell, W. S." box="[826,1098,1848,1867]" pageId="7" pageNumber="8" refId="ref8988" refString="Lippiello, P. M., Caldwell, W. S., 1993. Method for Treatment of Neurodegenerative Diseases. USA Patent, pp. 5242934." type="book" year="1993">Lippiello and Caldwell, 1993</bibRefCitation>
). The increase in nitrogen basicity in the pyrrolidine ring (compound 
<emphasis bold="true" box="[1087,1099,1876,1895]" pageId="7" pageNumber="8">7</emphasis>
) and incorporation of bulky substituents (compounds 
<emphasis bold="true" box="[940,952,1903,1922]" pageId="7" pageNumber="8">8</emphasis>
and 
<emphasis bold="true" box="[1000,1012,1903,1922]" pageId="7" pageNumber="8">9</emphasis>
) were both found to negatively impact the ability of the molecules to activate nAChRs. Nornicotine (
<emphasis bold="true" box="[1313,1325,1931,1950]" pageId="7" pageNumber="8">7</emphasis>
) showed similar agonistic efficacies for α4β2 and α7, but it was at least 20 times more potent for α4β2 than for α7 (
<subScript attach="left" box="[423,461,903,924]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
α4β2: 70% ± 11%; 
<subScript attach="left" box="[687,724,903,924]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
α7: 59.15% ± 15%, and EC 
<subScript attach="left" box="[335,353,939,951]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
α4β2: 4.92 ± 0.7 μM; EC 
<subScript attach="left" box="[607,625,939,951]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
α7&gt; 100 μM). Similar to the experiments in CHO cell lines, those in 
<taxonomicName _evidence="document" _step="document" box="[618,769,959,978]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="8" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[618,692,959,978]" italics="true" pageId="8" pageNumber="9">Xenopus</emphasis>
oocytes
</taxonomicName>
proved nornicotine (
<emphasis bold="true" box="[302,314,987,1006]" pageId="8" pageNumber="9">7</emphasis>
) to be a partial agonist of α4β2 and a weak agonist of α7 but with a high efficacy (EC 
<subScript attach="left" box="[491,509,1023,1035]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
α4β2: 3.12 ± 2.9 μM; 
<subScript attach="left" box="[733,770,1015,1036]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
α4β2: 19% ± 2%). The EC 
<subScript attach="left" box="[362,380,1051,1063]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
for α7 could not be fitted, as the current response did not reach a plateau at 300 μM (
<subScript attach="left" box="[545,583,1070,1091]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
α7: 70% ± 10%). Nornicotine (
<emphasis bold="true" box="[231,243,1098,1117]" pageId="8" pageNumber="9">7</emphasis>
) also produced pronounced effects on α3β4 nAChR (EC 
<subScript attach="left" box="[134,152,1135,1147]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 42.7 ± 2.8 μM; 
<subScript attach="left" box="[322,359,1126,1147]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 122% ± 18%).
</paragraph>
<caption ID-DOI="http://doi.org/10.5281/zenodo.8194191" ID-Zenodo-Dep="8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="8" pageNumber="9" startId="8.[100,130,738,755]" targetBox="[191,1397,165,712]" targetPageId="8" targetType="figure">
<paragraph blockId="8.[100,1488,737,857]" pageId="8" pageNumber="9">
<emphasis bold="true" box="[100,156,738,755]" pageId="8" pageNumber="9">Fig. 2.</emphasis>
Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator.
</paragraph>
</caption>
<paragraph blockId="8.[100,771,903,1982]" pageId="8" pageNumber="9">
Myosmine (
<emphasis bold="true" box="[246,271,1154,1173]" pageId="8" pageNumber="9">10</emphasis>
) and isomyosmine (
<emphasis bold="true" box="[467,492,1154,1173]" pageId="8" pageNumber="9">11</emphasis>
) have been found to exist in two forms, cyclic and linear. The latter is protonated at physiological pH, unlike the cyclic imine. While basicity of the pyrroline ring is insufficient to ensure interaction with nAChRs, the linear form of isomyosmine contains a fragment of 3-(aminomethyl)pyridine (
<bibRefCitation author="Glennon, R. A. &amp; Maarouf, A. &amp; Fahmy, S. &amp; Martin, B. &amp; Fan, F. &amp; Yousif, M. &amp; Shafik, R. M. &amp; Dukat, M." pageId="8" pageNumber="9" pagination="546 - 551" refId="ref8027" refString="Glennon, R. A., Maarouf, A., Fahmy, S., Martin, B., Fan, F., Yousif, M., Shafik, R. M., Dukat, M., 1993. Structure-activity relationships of simple nicotine analogs. Med. Chem. Res. 2, 546 - 551. https: // ci. nii. ac. jp / naid / 10011030393." type="journal article" year="1993">Glennon et al, 1993</bibRefCitation>
), which might contribute to the modest interaction of isomyosmine (
<emphasis bold="true" box="[214,239,1321,1340]" pageId="8" pageNumber="9">11</emphasis>
) with the α4β2 nAChR (EC 
<subScript attach="left" box="[515,533,1330,1342]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 30.5 ± 9.9 μM). When tested in oocytes at 33.3 μM, myosmine (
<emphasis bold="true" box="[509,534,1349,1368]" pageId="8" pageNumber="9">10</emphasis>
) and isomyosmine (
<emphasis bold="true" box="[737,762,1349,1368]" pageId="8" pageNumber="9">11</emphasis>
) failed to exert any agonistic effect on α4β2, α7, or α3β4 (
<tableCitation box="[657,728,1377,1396]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="8" pageNumber="9">Table 2</tableCitation>
and 
<tableCitation box="[100,172,1405,1424]" captionStart="Table 4" captionStartId="17.[100,150,161,177]" captionTargetId="graphics-1968@17.[627,1110,445,1284]" captionTargetPageId="17" captionText="Table 4 Heatmap of the tobacco alkaloids tested at 33.3 μM on human α7, α4β2, and α3β4 nAChRs stably expressed in CHO cells or transiently injected in Xenopus oocytes. The two-graded color scale between blue (weak) and red (potent) is differentially set to indicate potency (EC50, red ≤ 10 μM) and agonistic effect (IAGO, red ≥ 50% response relative to Imax ACh). The three-graded color scale between black (inhibition), green (no effect), and red (potentiation) is set for IAGO+ACh as follow; black ≥ 80% decrease relative to EC20 ACh; red ≥ 2x-fold increase relative to EC20 ACh. EC50, half-maximal effective concentration; h, human; nAChR, nicotinic acetylcholine receptors; AGO, agonist; IAGO, response of the agonist; IAGO+ACh, response of the agonist in the presence of the ACh EC20." pageId="8" pageNumber="9">Table 4</tableCitation>
).
</paragraph>
<paragraph blockId="8.[100,771,903,1982]" pageId="8" pageNumber="9">
Anabasine (
<emphasis bold="true" box="[246,271,1433,1452]" pageId="8" pageNumber="9">12</emphasis>
), a cyclic homolog of nornicotine (
<emphasis bold="true" box="[613,625,1433,1452]" pageId="8" pageNumber="9">7</emphasis>
), was the only alkaloid demonstrating greater agonist efficacy for α7 (
<subScript attach="left" box="[726,764,1461,1482]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 136% ± 53%) versus α4β2 and α3β4. Although it was more potent (but less effective) at opening α4β2 than α7, anabasine (
<emphasis bold="true" box="[641,666,1516,1535]" pageId="8" pageNumber="9">12</emphasis>
) displayed weak α4β2 agonistic effects (
<subScript attach="left" box="[405,443,1544,1565]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
α4β2: 12% ± 7%; EC 
<subScript attach="left" box="[682,700,1553,1565]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
α4β2: 0.9 ± 0.0 μM; EC 
<subScript attach="left" box="[271,289,1581,1593]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
α7: 42.6 ± 14.6 μM).
</paragraph>
<paragraph blockId="8.[100,771,903,1982]" pageId="8" pageNumber="9">
The results of the two-electrode voltage-clamp experiments in oocytes for anabasine (
<emphasis bold="true" box="[300,325,1628,1647]" pageId="8" pageNumber="9">12</emphasis>
) were comparable with those from the patch-clamp experiments in CHO cells. While anabasine (
<emphasis bold="true" box="[579,604,1656,1675]" pageId="8" pageNumber="9">12</emphasis>
) was the alkaloid with the greatest agonist efficacy for α7 and can be classified as a superagonist of this receptor, it was almost inefficacious against α4β2 and relatively active against α3β4 (
<subScript attach="left" box="[403,441,1740,1761]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 122% ± 10%, 3% ± 2.1%, and 82% ± 20%, respectively; EC 
<subScript attach="left" box="[413,431,1776,1788]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 15.45 ± 3.1, 4.41 ± 11, and 26.20 ± 3 μM, respectively).
</paragraph>
<paragraph blockId="8.[100,771,903,1982]" lastBlockId="8.[818,1488,903,1981]" pageId="8" pageNumber="9">
However, anabasine derivatives with small (compound 
<emphasis bold="true" box="[665,690,1823,1842]" pageId="8" pageNumber="9">13</emphasis>
) or aromatic (compounds 
<emphasis bold="true" box="[278,303,1851,1870]" pageId="8" pageNumber="9">14</emphasis>
, 
<emphasis bold="true" box="[314,339,1851,1870]" pageId="8" pageNumber="9">15</emphasis>
, 
<emphasis bold="true" box="[350,411,1851,1871]" pageId="8" pageNumber="9">20–23</emphasis>
) substituents were practically inactive against all nicotinic channels. Anatabine (
<emphasis bold="true" box="[500,525,1879,1898]" pageId="8" pageNumber="9">16</emphasis>
, 
<emphasis bold="true" box="[538,563,1879,1898]" pageId="8" pageNumber="9">17</emphasis>
) is a dehydrogenated analogue of anabasine. The incorporation of a double bond almost eliminated the weak agonism of anatabine for α7 nAChR without significantly influencing its interaction with α4β2 nAChR, although α4β2 nAChR exhibited stereochemical preference for the (
<emphasis bold="true" box="[1311,1325,903,922]" italics="true" pageId="8" pageNumber="9">R</emphasis>
)-enantiomer (for α4β2, S-anatabine [
<emphasis bold="true" box="[1009,1047,931,950]" pageId="8" pageNumber="9">16]</emphasis>
EC 
<subScript attach="left" box="[1080,1098,939,951]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
and 
<subScript attach="left" box="[1149,1186,931,952]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 7.7 ± 2.2 μM and 8% ± 1%, respectively; R-anatabine [
<emphasis bold="true" box="[1085,1110,958,977]" pageId="8" pageNumber="9">17</emphasis>
] EC 
<subScript attach="left" box="[1158,1176,967,979]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
and 
<subScript attach="left" box="[1238,1275,959,980]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 3.41 ± 0.8 μM and 23% ± 6%). The potency and efficacy of N-methylanatabine (
<emphasis bold="true" box="[1403,1428,986,1005]" pageId="8" pageNumber="9">18</emphasis>
) were comparable with those of (R)-anatabine (
<emphasis bold="true" box="[1266,1291,1014,1033]" pageId="8" pageNumber="9">17</emphasis>
) for α4β2 (EC 
<subScript attach="left" box="[1463,1481,1023,1035]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 6.2 ± 2.0 μM; 
<subScript attach="left" box="[963,1000,1043,1063]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 25.6% ± 1%).
</paragraph>
<paragraph blockId="8.[818,1488,903,1981]" pageId="8" pageNumber="9">
In oocytes, S-anatabine (
<emphasis bold="true" box="[1091,1116,1070,1089]" pageId="8" pageNumber="9">16</emphasis>
) was more effective than R-anatabine (
<emphasis bold="true" box="[826,851,1098,1117]" pageId="8" pageNumber="9">17</emphasis>
), with greater potency against α7. In contrast, both enantiomers showed similar potency and efficacy for the α4β2 nAChR (
<tableCitation box="[1400,1473,1126,1145]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="8" pageNumber="9">Table 2</tableCitation>
). Both compounds were also found to be partial agonists of the α3β4 nAChR, with moderate efficacies (S-anatabine, 
<subScript attach="left" box="[1280,1317,1182,1203]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 16% ± 7% and EC 
<subScript attach="left" box="[843,861,1218,1230]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 52.30 ± 3.8 μM; R-anatabine, 
<subScript attach="left" box="[1193,1230,1210,1231]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 43% ± 27% and EC 
<subScript attach="left" box="[1463,1481,1218,1230]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 37.70 ± 4.4 μM).
</paragraph>
<paragraph blockId="8.[818,1488,903,1981]" pageId="8" pageNumber="9">
Similarly, in the patch-clamp experiments, the potency and efficacy of N-methylanatabine (
<emphasis bold="true" box="[1034,1059,1293,1312]" pageId="8" pageNumber="9">18</emphasis>
) for α4β2 were comparable with those of (
<emphasis bold="true" box="[1459,1473,1293,1312]" italics="true" pageId="8" pageNumber="9">R</emphasis>
)- anatabine (
<emphasis bold="true" box="[926,951,1321,1340]" pageId="8" pageNumber="9">17</emphasis>
) (EC 
<subScript attach="left" box="[1001,1019,1330,1342]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 10.8 ± 3.5 μM; 
<subScript attach="right" box="[1191,1229,1322,1342]" fontSize="5" pageId="8" pageNumber="9">Imax</subScript>
: 6 ± 2%). In addition, Nmethylanatabine (
<emphasis bold="true" box="[989,1014,1349,1368]" pageId="8" pageNumber="9">18</emphasis>
) was also found to be a weak partial agonist of the α3β4 nAChR (
<tableCitation box="[956,1027,1377,1396]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="8" pageNumber="9">Table 2</tableCitation>
).
</paragraph>
<paragraph blockId="8.[818,1488,903,1981]" pageId="8" pageNumber="9">
Metanicotine (
<emphasis bold="true" box="[992,1004,1405,1424]" pageId="8" pageNumber="9">5</emphasis>
) was the most selective α4β2 agonist among all tobacco alkaloids tested with demonstrable nAChR activity, with a maximal response of 261.5% in CHO cell lines (151% in 
<taxonomicName _evidence="document" _step="document" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="8" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[1375,1449,1461,1480]" italics="true" pageId="8" pageNumber="9">Xenopus</emphasis>
oocytes
</taxonomicName>
), but without appreciable activation of α7 nAChR (
<tableCitation box="[1365,1445,1488,1508]" captionStart="Table 1" captionStartId="2.[100,150,161,177]" captionTargetPageId="2" captionText="Table 1 Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, agonist induced current at 3.7 μM; I33.3μM, agonist induced current at 33.3 μM." pageId="8" pageNumber="9">Tables 1</tableCitation>
and 
<tableCitation box="[818,830,1517,1536]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="8" pageNumber="9">2</tableCitation>
). Structurally related to metanicotine, pseudooxynicotines (
<emphasis bold="true" box="[1419,1479,1516,1536]" pageId="8" pageNumber="9">24–26</emphasis>
) appeared to be inactive in our experiments (
<tableCitation box="[1242,1322,1544,1563]" captionStart="Table 1" captionStartId="2.[100,150,161,177]" captionTargetPageId="2" captionText="Table 1 Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, agonist induced current at 3.7 μM; I33.3μM, agonist induced current at 33.3 μM." pageId="8" pageNumber="9">Tables 1</tableCitation>
and 
<tableCitation box="[1371,1383,1544,1563]" captionStart="Table 2" captionStartId="9.[100,150,161,177]" captionTargetPageId="9" captionText="Table 2 Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in Xenopus oocytes transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="8" pageNumber="9">2</tableCitation>
).
</paragraph>
<paragraph blockId="8.[818,1488,903,1981]" pageId="8" pageNumber="9">
Among the compounds from groups B, C, and D, only cotinine (
<emphasis bold="true" box="[1454,1479,1572,1591]" pageId="8" pageNumber="9">30</emphasis>
) displayed weak agonist activity for α4β2 (EC 
<subScript attach="left" box="[1281,1299,1609,1621]" fontSize="5" pageId="8" pageNumber="9">50</subScript>
: 85.3 ± 13.4 μM). Alkaloids from groups B, C, and D had negligible effects on α4β2 and α7 nAChRs, as they likely do not fit the common nicotinic pharmacophore model, which consists of two essential elements: a cationic center, typically a protonated amino group, and a hydrogen bond acceptor, often contained in a π-electron moiety such as the pyridine ring. The distance between these two elements varies from 4 Å to 7 Å (
<bibRefCitation author="Glennon, R. A. &amp; Dukat, M." box="[826,1073,1794,1813]" pageId="8" pageNumber="9" pagination="1841 - 1844" refId="ref7976" refString="Glennon, R. A., Dukat, M., 2004. α 4 β 2 nACh receptor pharmacophore models. Bioorg. Med. Chem. Lett 14, 1841 - 1844. https: // doi. org / 10.1016 / j. bmcl. 2003.07.035." type="journal article" year="2004">Glennon and Dukat, 2004</bibRefCitation>
). This pattern of essential pharmacophoric elements among the tobacco alkaloids in group A is consistent with our functional electrophysiological data on α4β2 and α7 nAChRs. However, additional work is required to establish a comprehensive pharmacophore model for other subtypes of the human nAChR family.
</paragraph>
<paragraph blockId="8.[818,1488,903,1981]" lastBlockId="11.[100,771,833,1969]" lastPageId="11" lastPageNumber="12" pageId="8" pageNumber="9">
A subset of the tobacco alkaloid library was screened at concentrations of 3.7 μM and/or 33.3 μM in the PAM mode (
<figureCitation box="[1383,1440,1961,1981]" captionStart="Fig" captionStartId="8.[100,130,738,755]" captionTargetBox="[191,1397,165,712]" captionTargetId="figure-959@8.[189,1399,152,715]" captionTargetPageId="8" captionText="Fig. 2. Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator." figureDoi="http://doi.org/10.5281/zenodo.8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="8" pageNumber="9">Fig. 2</figureCitation>
). To investigate the PAM potential of a given alkaloid, ionic currents were first elicited by applying the EC 
<subScript attach="left" box="[410,428,870,882]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
dose of ACh, after which the CHO cells were exposed to a given alkaloid for 2 min before a final cotreatment with the ACh EC 
<subScript attach="left" box="[312,330,926,938]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
dose (
<figureCitation box="[393,446,917,936]" captionStart="Fig" captionStartId="8.[100,130,738,755]" captionTargetBox="[191,1397,165,712]" captionTargetId="figure-959@8.[189,1399,152,715]" captionTargetPageId="8" captionText="Fig. 2. Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator." figureDoi="http://doi.org/10.5281/zenodo.8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="11" pageNumber="12">Fig. 2</figureCitation>
; see section 4.4). It is pertinent to mention that the EC 
<subScript attach="left" box="[297,315,954,966]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
concentration of ACh was selected in order to minimize the α4β2 and α7 current run-down over time (
<figureCitation box="[657,712,973,992]" captionStart="Fig" captionStartId="11.[100,130,694,711]" captionTargetBox="[265,1323,153,670]" captionTargetId="figure-886@11.[263,1324,152,671]" captionTargetPageId="11" captionText="Fig. 3. Sequential applications of brief ACh pulses are plotted as a function of time for three ACh concentrations. (a) EC20 = 0.4 μM (circles), EC50 = 1.2 μM (squares), EC90 = 11.1 μM (triangles) for human α4β2 receptors. (b) EC20 = 33.3 μM (circles), EC60 = 300 μM (squares), EC90 = 900 μM (triangles) for human α7 receptors. Experiments were performed by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing the human α4β2 and α7 nAChRs. EC, effective concentration. Data are presented as mean ± SD." figureDoi="http://doi.org/10.5281/zenodo.8194193" httpUri="https://zenodo.org/record/8194193/files/figure.png" pageId="11" pageNumber="12">Fig. 3</figureCitation>
). The EC 
<subScript attach="left" box="[126,144,1010,1022]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
ACh corresponded to 0.412 μM for α4β2 nAChRs and 100 μM for α7 nAChRs. A similar approach was used to investigate the PAM effects of the alkaloids in 
<taxonomicName _evidence="document" _step="document" box="[296,452,1057,1076]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="11" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[296,370,1057,1076]" italics="true" pageId="11" pageNumber="12">Xenopus</emphasis>
oocytes
</taxonomicName>
(see Supplementary 
<figureCitation box="[665,724,1057,1076]" captionStart="Fig" captionStartId="8.[100,130,738,755]" captionTargetBox="[191,1397,165,712]" captionTargetId="figure-959@8.[189,1399,152,715]" captionTargetPageId="8" captionText="Fig. 2. Representative traces of currents elicited by using the agonist mode (a and c) and PAM mode (b and d) in the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing human α4β2 (a and b) and human α7 (c and d) nAChRs. Agonist mode (a, c): 0.3% DMSO (left); 33.3 μM of the tobacco alkaloid anabasine (middle); 33.3 and 900 μM ACh for α4β2 and α7, respectively (right). PAM mode (b, d): 0.4 and 100 μM ACh for α4β2 and α7, respectively (left); co-application of 33.3 μM of the tobacco alkaloid trans-anatalline (middle); 0.4 or 100 μM ACh for α4β2 and α7, respectively (right). Thick dotted lines represent the pre-application period of the alkaloid (≥2 min). Thin dotted lines represent zero current.; PAM, positive allosteric modulator." figureDoi="http://doi.org/10.5281/zenodo.8194191" httpUri="https://zenodo.org/record/8194191/files/figure.png" pageId="11" pageNumber="12">Fig. 2</figureCitation>
and section 4.5). The electrophysiological patch-clamp and two-electrode voltage-clamp endpoint data of the PAM effects for the tobacco alkaloids are presented in 
<tableCitation box="[313,384,1140,1159]" captionStart="Table 3" captionStartId="12.[100,150,161,177]" captionTargetId="graphics-959@12.[782,793,1081,1095]" captionTargetPageId="12" captionText="Table 3 PAM effect – Tobacco alkaloids tested by the patch-clamp (CHO cells) and two-electrode voltage-clamp (Xenopus oocytes) assays for their efficacy against human α7, α4β2, and α3β4 nAChRs. Data values are preceded by (−) or (+) to indicate the inhibitory or potentiating effects, respectively, relative to the EC20 concentration of ACh (see section 4.4). Data are presented as mean ± SD. PAM, positive allosteric modulator. I3.7μM, induced current at 3.7 μM; I33.3μM, induced current at 33.3 μM." pageId="11" pageNumber="12">Table 3</tableCitation>
(see also 
<tableCitation box="[479,551,1140,1159]" captionStart="Table 4" captionStartId="17.[100,150,161,177]" captionTargetId="graphics-1968@17.[627,1110,445,1284]" captionTargetPageId="17" captionText="Table 4 Heatmap of the tobacco alkaloids tested at 33.3 μM on human α7, α4β2, and α3β4 nAChRs stably expressed in CHO cells or transiently injected in Xenopus oocytes. The two-graded color scale between blue (weak) and red (potent) is differentially set to indicate potency (EC50, red ≤ 10 μM) and agonistic effect (IAGO, red ≥ 50% response relative to Imax ACh). The three-graded color scale between black (inhibition), green (no effect), and red (potentiation) is set for IAGO+ACh as follow; black ≥ 80% decrease relative to EC20 ACh; red ≥ 2x-fold increase relative to EC20 ACh. EC50, half-maximal effective concentration; h, human; nAChR, nicotinic acetylcholine receptors; AGO, agonist; IAGO, response of the agonist; IAGO+ACh, response of the agonist in the presence of the ACh EC20." pageId="11" pageNumber="12">Table 4</tableCitation>
).
</paragraph>
<caption pageId="9" pageNumber="10" startId="9.[100,150,161,177]" targetBox="[54,1530,280,1972]" targetPageId="9" targetType="table">
<paragraph blockId="9.[100,1489,161,257]" box="[100,168,161,178]" pageId="9" pageNumber="10">
<emphasis bold="true" box="[100,168,161,178]" pageId="9" pageNumber="10">Table 2</emphasis>
</paragraph>
<paragraph blockId="9.[100,1489,161,257]" pageId="9" pageNumber="10">
Agonistic effect – Tobacco alkaloids tested by the two-electrode voltage-clamp assay in 
<taxonomicName _evidence="document" _step="document" box="[830,964,187,203]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="9" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[830,897,187,203]" italics="true" pageId="9" pageNumber="10">Xenopus</emphasis>
oocytes
</taxonomicName>
transiently injected with human α7, human α4β2, and human α3β4 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. EC 
<subScript attach="left" box="[237,253,244,256]" fontSize="5" pageId="9" pageNumber="10">50</subScript>
, half-maximal effective concentration; 
<subScript attach="left" box="[583,616,238,257]" fontSize="5" pageId="9" pageNumber="10">Imax</subScript>
, maximal response of the agonist; I 
<subScript attach="left" box="[912,953,244,256]" fontSize="5" pageId="9" pageNumber="10">3.7μM</subScript>
, induced current at 3.7 μM; I 
<subScript attach="right" box="[1196,1244,244,256]" fontSize="5" pageId="9" pageNumber="10">33.3μM</subScript>
, induced current at 33.3 μM.
</paragraph>
</caption>
<paragraph blockId="10.[100,266,160,178]" box="[100,266,160,178]" pageId="10" pageNumber="11">
<emphasis bold="true" box="[100,168,161,178]" pageId="10" pageNumber="11">Table 2</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="10" pageNumber="11">continued</emphasis>
)
</paragraph>
<caption ID-DOI="http://doi.org/10.5281/zenodo.8194193" ID-Zenodo-Dep="8194193" httpUri="https://zenodo.org/record/8194193/files/figure.png" pageId="11" pageNumber="12" startId="11.[100,130,694,711]" targetBox="[265,1323,153,670]" targetPageId="11" targetType="figure">
<paragraph blockId="11.[100,1488,693,788]" pageId="11" pageNumber="12">
<emphasis bold="true" box="[100,160,694,711]" pageId="11" pageNumber="12">Fig. 3.</emphasis>
Sequential applications of brief ACh pulses are plotted as a function of time for three ACh concentrations. (a) EC 
<subScript attach="left" box="[1172,1188,701,713]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
= 0.4 μM (circles), EC 
<subScript attach="left" box="[1386,1402,701,713]" fontSize="5" pageId="11" pageNumber="12">50</subScript>
= 1.2 μM (squares), EC 
<subScript attach="left" box="[213,229,727,739]" fontSize="5" pageId="11" pageNumber="12">90</subScript>
= 11.1 μM (triangles) for human α4β2 receptors. (b) EC 
<subScript attach="left" box="[716,732,727,739]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
= 33.3 μM (circles), EC 
<subScript attach="left" box="[937,953,727,739]" fontSize="5" pageId="11" pageNumber="12">60</subScript>
= 300 μM (squares), EC 
<subScript attach="left" box="[1162,1178,727,739]" fontSize="5" pageId="11" pageNumber="12">90</subScript>
= 900 μM (triangles) for human α7 receptors. Experiments were performed by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing the human α4β2 and α7 nAChRs. EC, effective concentration. Data are presented as mean ± SD.
</paragraph>
</caption>
<paragraph blockId="11.[100,771,833,1969]" pageId="11" pageNumber="12">
We defined a relevant PAM as a compound that potentiated the ACh EC 
<subScript attach="left" box="[126,144,1205,1217]" fontSize="5" pageId="11" pageNumber="12">20</subScript>
-induced peak current by at least two-fold without displaying any agonistic effects. While no compound with PAM properties was identified, several alkaloids inhibited the ACh-induced response of both nAChRs. On the basis of our data, we could not distinguish competitive/ non-competitive antagonists from negative allosteric modulators (NAMs). Thirteen alkaloids were identified as inhibitors of the ACh-induced α4β2 nAChR current (by ≥ 80%) without showing any agonistic activity (at least up to 33.3 μM). In order of degree of inhibition, these were compounds 
<emphasis bold="true" box="[326,351,1419,1438]" pageId="11" pageNumber="12">37</emphasis>
, 
<emphasis bold="true" box="[364,376,1419,1438]" pageId="11" pageNumber="12">8</emphasis>
, 
<emphasis bold="true" box="[391,416,1419,1438]" pageId="11" pageNumber="12">13</emphasis>
, 
<emphasis bold="true" box="[429,454,1419,1438]" pageId="11" pageNumber="12">14</emphasis>
, 
<emphasis bold="true" box="[468,493,1419,1438]" pageId="11" pageNumber="12">36</emphasis>
, 
<emphasis bold="true" box="[507,532,1419,1438]" pageId="11" pageNumber="12">54</emphasis>
, 
<emphasis bold="true" box="[545,570,1419,1438]" pageId="11" pageNumber="12">40</emphasis>
, 
<emphasis bold="true" box="[584,609,1419,1438]" pageId="11" pageNumber="12">45</emphasis>
, 
<emphasis bold="true" box="[623,648,1419,1438]" pageId="11" pageNumber="12">10</emphasis>
, 
<emphasis bold="true" box="[662,687,1419,1438]" pageId="11" pageNumber="12">68</emphasis>
, 
<emphasis bold="true" box="[700,725,1419,1438]" pageId="11" pageNumber="12">33</emphasis>
, 
<emphasis bold="true" box="[739,764,1419,1438]" pageId="11" pageNumber="12">34</emphasis>
, and 
<emphasis bold="true" box="[142,167,1447,1466]" pageId="11" pageNumber="12">65</emphasis>
. Nine alkaloids were found to be α7 nAChR inhibitors with no agonistic effects (
<emphasis bold="true" box="[263,288,1475,1494]" pageId="11" pageNumber="12">54</emphasis>
, 
<emphasis bold="true" box="[299,311,1475,1494]" pageId="11" pageNumber="12">5</emphasis>
, 
<emphasis bold="true" box="[323,348,1475,1494]" pageId="11" pageNumber="12">37</emphasis>
, 
<emphasis bold="true" box="[359,384,1475,1494]" pageId="11" pageNumber="12">36</emphasis>
, 
<emphasis bold="true" box="[396,421,1475,1494]" pageId="11" pageNumber="12">16</emphasis>
, 
<emphasis bold="true" box="[432,457,1475,1494]" pageId="11" pageNumber="12">17</emphasis>
, 
<emphasis bold="true" box="[468,493,1475,1494]" pageId="11" pageNumber="12">23</emphasis>
, 
<emphasis bold="true" box="[504,529,1475,1494]" pageId="11" pageNumber="12">13</emphasis>
, and 
<emphasis bold="true" box="[581,606,1475,1494]" pageId="11" pageNumber="12">14</emphasis>
). Despite the fact that metanicotine (
<emphasis bold="true" box="[287,299,1503,1522]" pageId="11" pageNumber="12">5</emphasis>
) and S- and R-anatabine (
<emphasis bold="true" box="[563,588,1503,1522]" pageId="11" pageNumber="12">16</emphasis>
and 
<emphasis bold="true" box="[641,666,1503,1522]" pageId="11" pageNumber="12">17</emphasis>
) activated α4β2, we only detected their strong inhibitory effects against human α7 nAChR. Additionally, we identified 6-hydroxykynurenic acid (
<emphasis bold="true" box="[737,762,1559,1578]" pageId="11" pageNumber="12">54</emphasis>
) (
<bibRefCitation author="Macnicol, P. K." box="[108,258,1587,1606]" pageId="11" pageNumber="12" refId="ref9135" refString="Macnicol, P. K., 1968. Isolation for 6 - hydroxykynurenic acid from the tobacco leaf. Biochem. J. 473 - 479 PMID: 5665251." type="journal volume" year="1968">Macnicol, 1968</bibRefCitation>
), a tryptophan metabolite, as a dual α4β2 and α7 nAChR-inhibitory alkaloid. Interestingly, 6-hydroxykynurenic acid (
<emphasis bold="true" box="[737,762,1614,1633]" pageId="11" pageNumber="12">54</emphasis>
) has already been shown to differentially inhibit other neuronal ion channels, such as AMPA and NMDA receptors, in hippocampal neurons, suggesting a wider role as an endogenous inhibitor (
<bibRefCitation author="Weber, M. &amp; Dietrich, D. &amp; Grasel, I. &amp; Reuter, G. &amp; Seifert, G. &amp; Steinhauser, C." box="[585,756,1698,1718]" pageId="11" pageNumber="12" pagination="1108 - 1115" refId="ref10342" refString="Weber, M., Dietrich, D., Grasel, I., Reuter, G., Seifert, G., Steinhauser, C., 2001. 6 - Hydroxykynurenic acid and kynurenic acid differently antagonise AMPA and NMDA receptors in hippocampal neurones. J. Neurochem. 1108 - 1115. https: // doi. org / 10. 1046 / j. 1471 - 4159.2001.00340. x." type="book chapter" year="2001">Weber et al., 2001</bibRefCitation>
).
</paragraph>
<paragraph blockId="11.[100,771,833,1969]" lastBlockId="11.[818,1488,833,1857]" pageId="11" pageNumber="12">
The two approaches most commonly used for heterologous expression of cloned ion channels and transporters involve transfection of the genes into cells grown in tissue culture or injection of the genetic material into larger cells (
<bibRefCitation author="Kirsch &amp; Glenn E. &amp; Fedorov &amp; Nikolai B. &amp; Kuryshev &amp; Yuri A. &amp; Liu, Zhiqi &amp; Armstrong &amp; Lucas C. &amp; Orr &amp; Michael S." box="[324,501,1810,1829]" pageId="11" pageNumber="12" pagination="333 - 344" refId="ref8704" refString="Kirsch, Glenn E., Fedorov, Nikolai B., Kuryshev, Yuri A., Liu, Zhiqi, Armstrong, Lucas C., Orr, Michael S., 2016. Electrophysiology-based assays to detect subtype-selective modulation of human nicotinic acetylcholine receptors. Assay Drug Dev. Technol. 14 (6), 333 - 344. https: // doi. org / 10.1089 / adt. 2015.688." type="journal article" year="2016">Kirsch et al., 2016</bibRefCitation>
; Papke and Smith-Maxwell, 2009). We used both approaches—mammalian cell lines and 
<taxonomicName _evidence="document" _step="document" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="11" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[696,770,1838,1857]" italics="true" pageId="11" pageNumber="12">Xenopus</emphasis>
oocytes
</taxonomicName>
—for compound validation because some channels express more readily in oocytes than in mammalian cells and vice versa. We observed a shift in the concentration–response curves of many compounds when comparing EC50 values between 
<taxonomicName _evidence="document" _step="document" box="[411,561,1950,1969]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="11" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[411,485,1950,1969]" italics="true" pageId="11" pageNumber="12">Xenopus</emphasis>
oocytes
</taxonomicName>
and mammalian CHO cells. The possible reasons for this inequality in compound potency have not been clearly investigated, but the discrepancy can be attributed to several differences in post-translational processing of proteins, the diverse composition of the cell membrane, and dissimilarities in extracellular ion concentrations during electrophysiological analysis of oocytes and mammalian cell lines (
<bibRefCitation author="Burton, R. F." box="[1151,1275,973,992]" pageId="11" pageNumber="12" pagination="663 - 671" refId="ref7691" refString="Burton, R. F., 1983. The composition of animal cells: solutes contributing to osmotic pressure and charge balance. Comp. Biochem. Physiol. B 76 (4), 663 - 671. https: // doi. org / 10.1016 / 0305 - 0491 (83) 90375 - 9." type="journal article" year="1983">Burton, 1983</bibRefCitation>
, 
<bibRefCitation author="Josefsberg, Ben-Yehoshua &amp; Nava" pageId="11" pageNumber="12" pagination="161 - 171" refId="ref8590" refString="Josefsberg, Ben-Yehoshua, Nava, Dekel, 2002. Translational and post-translational modifications in meiosis of the mammalian oocyte. Mol. Cell. Endocrinol. 187, 161 - 171. https: // doi. org / 10.1016 / S 0303 - 7207 (01) 00688 - 8. Issues 1 - 2." type="journal article" year="2002">Josefsberg and Nava, 2002</bibRefCitation>
).
</paragraph>
<paragraph blockId="11.[818,1488,833,1857]" pageId="11" pageNumber="12">
When consuming tobacco products, the free plasma concentration of nicotine, nornicotine, anabasine, and anatabine has been reported to range from 0.06 to 0.6 μM (
<bibRefCitation author="Miller, E. I. &amp; Norris, HR &amp; Rollins, DE &amp; Tiffany, S. T. &amp; Wilkins, D. G." box="[1098,1279,1085,1104]" pageId="11" pageNumber="12" pagination="725 - 737" refId="ref9405" refString="Miller, E. I., Norris, HR, Rollins, DE, Tiffany, S. T., Wilkins, D. G., 2009. A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometr. J Chromatogr. B Anal. Technol. Biomed. Life Sci. 725 - 737. https: // doi. org / 10.1016 / j. jchromb. 2009.12.018." type="book chapter" year="2009">Miller et al., 2009</bibRefCitation>
, 
<bibRefCitation author="Jacob III, P L Yu &amp; Shulgin, A. T. &amp; Benowitz, N. L." box="[1294,1473,1085,1104]" pageId="11" pageNumber="12" refId="ref8471" refString="Jacob III, P L Yu, Shulgin, A. T., Benowitz, N. L., 1999. Minor tobacco alkaloids as biomarkers for tobacco use: comparison ofUsers of Cigarettes, smokeless tobacco, cigars, and pipes. Am. J. Public Health 731 - 736 PMID: 10224986." type="journal volume" year="1999">Jacob et al., 1999</bibRefCitation>
). While the absolute concentration of tobacco alkaloids present at synapses is unknown, the levels of nicotine in the cerebrospinal fluid of smokers have been found to be high (up to 1.3 μM), double that reported in plasma (
<bibRefCitation author="Malkawia, A. H. &amp; Al-Ghananeema, A. M. &amp; Leon, Jd &amp; Crooks, P. A." box="[1004,1223,1196,1216]" pageId="11" pageNumber="12" pagination="132" refId="ref9166" refString="Malkawia, A. H., Al-Ghananeema, A. M., Leon, Jd, Crooks, P. A., 2008. Nicotine exposure can be detected in cerebrospinal fluid of active. J. Pharm. Biomed. Anal. 129, 132. https: // doi. org / 10.1016 / j. jpba. 2008.10.003." type="journal article" year="2008">Malkawia et al., 2008</bibRefCitation>
). We found four alkaloids (nicotine, nornicotine, anabasine, and R-anatabine) with potencies below 5 μM for α4β2; these compounds represent the most abundant alkaloids present in commercial tobacco plants (
<bibRefCitation author="Saitoh, F. &amp; Nona, M. &amp; Kawashima, N." box="[1292,1473,1280,1299]" pageId="11" pageNumber="12" pagination="477 - 480" refId="ref9989" refString="Saitoh, F., Nona, M., Kawashima, N., 1985. The alkaloid contents of sixty Nicotiana species. Phytochemistry 24, 477 - 480. https: // doi. org / 10.1016 / S 0031 - 9422 (00) 80751 - 7." type="journal article" year="1985">Saitoh et al., 1985</bibRefCitation>
). Interestingly, none of the alkaloids displayed such potency (&lt;5 μM) against the α7 and α3β4 subtypes. Although their EC 
<subScript attach="left" box="[1340,1358,1345,1357]" fontSize="5" pageId="11" pageNumber="12">50</subScript>
for α4β2 receptors (0.79–4.92 μM; 
<tableCitation box="[1043,1115,1363,1383]" captionStart="Table 1" captionStartId="2.[100,150,161,177]" captionTargetPageId="2" captionText="Table 1 Agonistic effect – Tobacco alkaloids tested by the patch-clamp electrophysiological assay in CHO cells stably expressing human α4β2 and α7 nAChRs. Data values represent the agonistic effects (percent activation) as a function of the maximal response to ACh (see section 4.4). Data are presented as mean ± SD. *concentration = 11.1 μM; EC50, half-maximal effective concentration; Imax, maximal response of the agonist; I3.7μM, agonist induced current at 3.7 μM; I33.3μM, agonist induced current at 33.3 μM." pageId="11" pageNumber="12">Table 1</tableCitation>
) is outside their expected plasma concentration in tobacco users (0.06–0.6 μM), channel opening can nevertheless be anticipated at these concentrations (
<figureCitation box="[1330,1387,1419,1438]" captionStart="Fig" captionStartId="18.[100,130,818,835]" captionTargetBox="[107,755,154,793]" captionTargetId="figure-817@18.[105,766,152,796]" captionTargetPageId="18" captionText="Fig. 4. Concentration–response curves were obtained by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV from CHO cells stably expressing human α4β2 (continuous black lines) or human α7 (dotted grey lines) nAChRs. The lines represent the fits to the Hill equation for nicotine (1) (circles symbols), anabasine (12) (triangles symbols), nornicotine (7) (squared symbols), and S-anatabine (16) (diamonds symbols). The fit parameters are presented (Table 1). The averaged normalized current response is plotted as a function of the maximal current to ACh (ImaxACh). Two backgrounds highlight the concentration range of the tobacco alkaloids levels measured in human plasma (grey background with diagonal lines) and in human cerebrospinal fluid (grey background with horizontal lines). Data are presented as mean ± SD." figureDoi="http://doi.org/10.5281/zenodo.8194195" httpUri="https://zenodo.org/record/8194195/files/figure.png" pageId="11" pageNumber="12">Fig. 4</figureCitation>
). Furthermore, certain pathological conditions (e.g., kidney failure or exposure to medications inhibiting nicotine clearance by CYPA6) might cause an increase in the levels of tobacco alkaloids (
<bibRefCitation author="Hukkanen, J. &amp; Jacob III, P. &amp; Benowitz, N. L." box="[1252,1473,1503,1522]" pageId="11" pageNumber="12" pagination="115" refId="ref8423" refString="Hukkanen, J., Jacob III, P., Benowitz, N. L., 2005. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 79, 115. https: // doi. org / 10.1124 / pr. 57.1.3." type="journal article" year="2005">Hukkanen et al., 2005</bibRefCitation>
). Therefore, the physiological and pathological concentrations of the main tobacco alkaloids in tobacco users most likely reach sufficient levels to uniquely impact the function of α4β2 nAChRs.
</paragraph>
<paragraph blockId="11.[818,1488,833,1857]" pageId="11" pageNumber="12">
Gaining a better understanding of nicotine's interaction with diverse receptor subtypes with therapeutic potential has helped to develop clinical drug candidates for neuropathological conditions such as Alzheimer's disease, ADHD, pain, schizophrenia, and major depression (
<bibRefCitation author="Yang, Taoyi &amp; Xiao, Ting &amp; Sun, Qi" box="[826,995,1726,1745]" pageId="11" pageNumber="12" pagination="611 - 622" refId="ref10492" refString="Yang, Taoyi, Xiao, Ting, Sun, Qi, Wanga, Kewei, 2017. The current agonists and positive allosteric modulators of α 7 nAChR for CNS indications in clinical trials. Acta Pharm. Sin. B 611 - 622. https: // doi. org / 10.1016 / j. apsb. 2017.09.001." type="book chapter" year="2017">Yang et al., 2017</bibRefCitation>
; 
<bibRefCitation author="Echeverria, V." box="[1010,1174,1726,1745]" pageId="11" pageNumber="12" pagination="1 - 9" refId="ref7877" refString="Echeverria, V., 2012. Cotinine: beyond that expected, more than a biomarker of tobacco consumption. Front. Pharmacol. 3, 1 - 9. https: // doi. org / 10.3389 / fphar. 2012.00173." type="journal article" year="2012">Echeverria, 2012</bibRefCitation>
). The electrophysiological characterization of the tobacco alkaloids presented in our manuscript would help to better understand the interactions of the tobacco alkaloids with the diverse nAChR subtypes and, optimistically, facilitate the development of appropriate scaffolds for further drug development.
</paragraph>
</subSection>
<subSection _generate="added" lastPageId="16" lastPageNumber="17" pageId="11" pageNumber="12" type="multiple">
<paragraph blockId="11.[818,970,1916,1935]" box="[818,970,1916,1935]" pageId="11" pageNumber="12">
<heading bold="true" box="[818,970,1916,1935]" fontSize="36" level="1" pageId="11" pageNumber="12" reason="1">
<emphasis bold="true" box="[818,970,1916,1935]" pageId="11" pageNumber="12">3. Conclusions</emphasis>
</heading>
</paragraph>
<paragraph blockId="11.[851,1487,1972,1992]" lastBlockId="16.[100,771,1293,1842]" lastPageId="16" lastPageNumber="17" pageId="11" pageNumber="12">In summary, 71 tobacco alkaloids were categorized into four groups on the basis of nAChR pharmacophoric elements and characterized by automated electrophysiological assays. We demonstrated that tobacco alkaloids containing pyridine as a hydrogen bond acceptor and a basic nitrogen atom—pharmacophoric elements necessary for molecular recognition by nAChRs—stimulated both α4β2 and α7 nAChRs with varying degrees of selectivity, potency, and efficacy. Four alkaloids—nicotine, nornicotine, anabasine and R-anatabine—potently activated α4β2 and weakly activated α7 nAChRs. While nicotine was the most potent α4β2 agonist, cotinine was the weakest among the active alkaloids. Anabasine produced the highest α7 activation. Metanicotine was the most selective α4β2 agonist and exerted maximum efficacy. The tobacco alkaloids did not enhance the nAChR activity elicited by the endogenous ligand ACh (i.e., they were not PAMs of α4β2 or α7 nAChRs) but rather acted as inhibitory compounds of both receptors by reducing the channel function evoked by ACh. In conclusion, we have demonstrated the pharmacological characteristics of an entire panel of tobacco alkaloids by using human α4β2 and α7 nAChRs to provide evidence that the human α4β2 nAChR is a pharmacologically relevant target for sensing the physiological concentrations of the most abundant alkaloids present in tobacco plants.</paragraph>
</subSection>
<caption pageId="12" pageNumber="13" startId="12.[100,150,161,177]" targetBox="[45,1527,271,1903]" targetPageId="12" targetType="table">
<paragraph blockId="12.[100,1489,161,256]" box="[100,168,161,178]" pageId="12" pageNumber="13">
<emphasis bold="true" box="[100,168,161,178]" pageId="12" pageNumber="13">Table 3</emphasis>
</paragraph>
<paragraph blockId="12.[100,1489,161,256]" pageId="12" pageNumber="13">
PAM effect – Tobacco alkaloids tested by the patch-clamp (CHO cells) and two-electrode voltage-clamp (
<taxonomicName _evidence="document" _step="document" box="[980,1117,185,203]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="12" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[980,1047,187,203]" italics="true" pageId="12" pageNumber="13">Xenopus</emphasis>
oocytes
</taxonomicName>
) assays for their efficacy against human α7, α4β2, and α3β4 nAChRs. Data values are preceded by (−) or (+) to indicate the inhibitory or potentiating effects, respectively, relative to the EC 
<subScript attach="left" box="[1328,1344,219,231]" fontSize="5" pageId="12" pageNumber="13">20</subScript>
concentration of ACh (see section 4.4). Data are presented as mean ± SD. PAM, positive allosteric modulator. I 
<subScript attach="left" box="[904,945,244,256]" fontSize="5" pageId="12" pageNumber="13">3.7μM</subScript>
, induced current at 3.7 μM; I 
<subScript attach="left" box="[1192,1241,244,256]" fontSize="5" pageId="12" pageNumber="13">33.3μM</subScript>
, induced current at 33.3 μM.
</paragraph>
</caption>
<paragraph blockId="12.[1286,1487,1936,1954]" box="[1286,1487,1936,1954]" pageId="12" pageNumber="13">
<tableNote box="[1286,1487,1936,1954]" pageId="12" pageNumber="13">
(
<emphasis bold="true" box="[1293,1480,1936,1953]" italics="true" pageId="12" pageNumber="13">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="13.[100,266,160,178]" box="[100,266,160,178]" pageId="13" pageNumber="14">
<emphasis bold="true" box="[100,168,161,178]" pageId="13" pageNumber="14">Table 3</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="13" pageNumber="14">continued</emphasis>
)
</paragraph>
<paragraph blockId="13.[1286,1487,1374,1392]" box="[1286,1487,1374,1392]" pageId="13" pageNumber="14">
<tableNote box="[1286,1487,1374,1392]" pageId="13" pageNumber="14">
(
<emphasis bold="true" box="[1293,1480,1375,1392]" italics="true" pageId="13" pageNumber="14">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="14.[100,266,160,178]" box="[100,266,160,178]" pageId="14" pageNumber="15">
<emphasis bold="true" box="[100,168,161,178]" pageId="14" pageNumber="15">Table 3</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="14" pageNumber="15">continued</emphasis>
)
</paragraph>
<paragraph blockId="14.[1286,1487,1533,1552]" box="[1286,1487,1533,1552]" pageId="14" pageNumber="15">
<tableNote box="[1286,1487,1533,1552]" pageId="14" pageNumber="15">
(
<emphasis bold="true" box="[1293,1480,1534,1551]" italics="true" pageId="14" pageNumber="15">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="15.[100,266,160,178]" box="[100,266,160,178]" pageId="15" pageNumber="16">
<emphasis bold="true" box="[100,168,161,178]" pageId="15" pageNumber="16">Table 3</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="15" pageNumber="16">continued</emphasis>
)
</paragraph>
<paragraph blockId="15.[1286,1487,1525,1543]" box="[1286,1487,1525,1543]" pageId="15" pageNumber="16">
<tableNote box="[1286,1487,1525,1543]" pageId="15" pageNumber="16">
(
<emphasis bold="true" box="[1293,1480,1526,1543]" italics="true" pageId="15" pageNumber="16">continued on next page</emphasis>
)
</tableNote>
</paragraph>
<paragraph blockId="16.[100,266,160,178]" box="[100,266,160,178]" pageId="16" pageNumber="17">
<emphasis bold="true" box="[100,168,161,178]" pageId="16" pageNumber="17">Table 3</emphasis>
(
<emphasis bold="true" box="[182,260,161,178]" italics="true" pageId="16" pageNumber="17">continued</emphasis>
)
</paragraph>
<subSection _generate="added" box="[818,983,1292,1311]" pageId="16" pageNumber="17" type="multiple">
<paragraph blockId="16.[818,983,1292,1311]" box="[818,983,1292,1311]" pageId="16" pageNumber="17">
<heading bold="true" box="[818,983,1292,1311]" fontSize="36" level="1" pageId="16" pageNumber="17" reason="1">
<emphasis bold="true" box="[818,983,1292,1311]" pageId="16" pageNumber="17">4. Experimental</emphasis>
</heading>
</paragraph>
</subSection>
<subSection _generate="added" pageId="16" pageNumber="17" type="multiple">
<paragraph blockId="16.[818,947,1348,1367]" box="[818,947,1348,1367]" pageId="16" pageNumber="17">
<heading bold="true" box="[818,947,1348,1367]" fontSize="36" level="1" pageId="16" pageNumber="17" reason="1">
<emphasis bold="true" box="[818,947,1348,1367]" italics="true" pageId="16" pageNumber="17">4.1. Alkaloids</emphasis>
</heading>
</paragraph>
<paragraph blockId="16.[818,1488,1404,1619]" pageId="16" pageNumber="17">
Alkaloids (of ACS reagent-grade purity or higher) were purchased from commercial sources or provided by WuXi AppTec Co., Ltd. (
<collectingRegion box="[824,915,1460,1479]" country="China" name="Shanghai" pageId="16" pageNumber="17">Shanghai</collectingRegion>
, 
<collectingCountry box="[924,981,1460,1479]" name="China" pageId="16" pageNumber="17">China</collectingCountry>
) and Selvita S.A. (Krakow, 
<collectingCountry box="[1237,1307,1460,1479]" name="Poland" pageId="16" pageNumber="17">Poland</collectingCountry>
). Stock solutions of the alkaloids were prepared as 100 mM solutions in dimethyl sulfoxide (DMSO) and stored at −20 °C. All chemicals were prepared daily in external recording solutions and diluted to appropriate concentrations for electrophysiological recordings. Compound solutions contained 0.3% DMSO and were prepared in 96-well compound plates.
</paragraph>
</subSection>
<subSection _generate="added" lastPageId="17" lastPageNumber="18" pageId="16" pageNumber="17" type="multiple">
<paragraph blockId="16.[818,966,1665,1684]" box="[818,966,1665,1684]" pageId="16" pageNumber="17">
<heading bold="true" box="[818,966,1665,1684]" fontSize="36" level="1" pageId="16" pageNumber="17" reason="1">
<emphasis bold="true" box="[818,966,1665,1684]" italics="true" pageId="16" pageNumber="17">4.2. Cell culture</emphasis>
</heading>
</paragraph>
<paragraph blockId="16.[818,1488,1721,1991]" lastBlockId="17.[100,770,1331,1657]" lastPageId="17" lastPageNumber="18" pageId="16" pageNumber="17">
CHO cell lines stably expressing human α7/Ric3 nAChR (hα7/Ric3 nAChR-CHO) and human α4β2 nAChR (hα4β2 nAChR-CHO) were obtained from Charles River Laboratories (Wilmington, MA, 
<collectingCountry box="[1388,1434,1777,1796]" name="United States of America" pageId="16" pageNumber="17">USA</collectingCountry>
). The cells were maintained in DMEM/F12 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, 
<collectingCountry box="[1087,1130,1833,1852]" name="United States of America" pageId="16" pageNumber="17">USA</collectingCountry>
) supplemented with 10% heat-inactivated fetal bovine serum (Gibco) and penicillin–streptomycin (100 U/mL and 
<quantity box="[921,985,1889,1908]" metricMagnitude="-7" metricUnit="kg" metricValue="1.0" pageId="16" pageNumber="17" unit="mg" value="0.1">0.1 mg</quantity>
/mL, respectively) solution (Sigma-Aldrich, St. Louis, MO, 
<collectingCountry box="[866,909,1917,1936]" name="United States of America" pageId="16" pageNumber="17">USA</collectingCountry>
) at 37 °C in 5% CO 
<subScript attach="left" box="[1101,1110,1926,1938]" fontSize="5" pageId="16" pageNumber="17">2</subScript>
and 70% humidity. Hα7/Ric3 nAChR-CHO cells were continuously cultured in the presence of G418 (
<quantity box="[824,902,1972,1991]" metricMagnitude="-7" metricUnit="kg" metricValue="2.5" pageId="16" pageNumber="17" unit="mg" value="0.25">0.25 mg</quantity>
/mL, Sigma-Aldrich) and zeocin (
<quantity box="[1223,1289,1972,1991]" metricMagnitude="-7" metricUnit="kg" metricValue="4.0" pageId="16" pageNumber="17" unit="mg" value="0.4">0.4 mg</quantity>
/mL, InvivoGen, San Diego, CA, 
<collectingCountry box="[207,253,1331,1350]" name="United States of America" pageId="17" pageNumber="18">USA</collectingCountry>
). Hα4β2 nAChR CHO cells were continuously cultured in the presence of puromycin (8 μg/mL, InvivoGen) and hygromycin (
<quantity box="[107,172,1387,1406]" metricMagnitude="-7" metricUnit="kg" metricValue="4.0" pageId="17" pageNumber="18" unit="mg" value="0.4">0.4 mg</quantity>
/mL, Gibco) per manufacturer protocols.
</paragraph>
<caption pageId="17" pageNumber="18" startId="17.[100,150,161,177]" targetBox="[113,1474,325,1283]" targetPageId="17" targetType="table">
<paragraph blockId="17.[100,1489,161,307]" box="[100,168,161,178]" pageId="17" pageNumber="18">
<emphasis bold="true" box="[100,168,161,178]" pageId="17" pageNumber="18">Table 4</emphasis>
</paragraph>
<paragraph blockId="17.[100,1489,161,307]" pageId="17" pageNumber="18">
Heatmap of the tobacco alkaloids tested at 33.3 μM on human α7, α4β2, and α3β4 nAChRs stably expressed in CHO cells or transiently injected in 
<taxonomicName _evidence="document" _step="document" box="[1346,1484,187,203]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="17" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[1346,1413,187,203]" italics="true" pageId="17" pageNumber="18">Xenopus</emphasis>
oocytes
</taxonomicName>
. The two-graded color scale between blue (weak) and red (potent) is differentially set to indicate potency (EC 
<subScript attach="left" box="[1023,1039,219,231]" fontSize="5" pageId="17" pageNumber="18">50</subScript>
, red ≤ 10 μM) and agonistic effect (IAGO, red ≥ 50% response relative to 
<subScript attach="left" box="[278,312,238,257]" fontSize="5" pageId="17" pageNumber="18">Imax</subScript>
ACh). The three-graded color scale between black (inhibition), green (no effect), and red (potentiation) is set for IAGO 
<subScript attach="right" box="[1358,1396,244,256]" fontSize="5" pageId="17" pageNumber="18">+ACh</subScript>
as follow; black ≥ 80% decrease relative to EC 
<subScript attach="left" box="[414,430,270,282]" fontSize="5" pageId="17" pageNumber="18">20</subScript>
ACh; red ≥ 2x-fold increase relative to EC 
<subScript attach="left" box="[799,815,270,282]" fontSize="5" pageId="17" pageNumber="18">20</subScript>
ACh. EC 
<subScript attach="right" box="[894,910,270,282]" fontSize="5" pageId="17" pageNumber="18">50</subScript>
, half-maximal effective concentration; h, human; nAChR, nicotinic acetylcholine receptors; AGO, agonist; IAGO, response of the agonist; IAGO 
<subScript attach="right" box="[730,768,295,307]" fontSize="5" pageId="17" pageNumber="18">+ACh</subScript>
, response of the agonist in the presence of the ACh EC 
<subScript attach="right" box="[1241,1257,295,307]" fontSize="5" pageId="17" pageNumber="18">20</subScript>
.
</paragraph>
</caption>
<paragraph blockId="17.[100,770,1331,1657]" pageId="17" pageNumber="18">
For patch-clamp experiments, the cells were seeded in 
<quantity box="[665,729,1415,1434]" metricMagnitude="-2" metricUnit="m" metricValue="6.0" pageId="17" pageNumber="18" unit="mm" value="60.0">60 mm</quantity>
cell culture dishes. Six hours later, the cells were transferred to a 30 °C incubator (5% CO 
<subScript attach="left" box="[251,260,1480,1492]" fontSize="5" pageId="17" pageNumber="18">2</subScript>
, 70% humidity) and cultured for 1–4 days to enhance nAChR expression (
<bibRefCitation author="Lin, C. Y. &amp; Huang, Z. &amp; Wen, W. &amp; Wu, A. &amp; Wang, C. &amp; Niu, L." box="[300,465,1498,1518]" pageId="17" pageNumber="18" pagination="0123562" refId="ref8917" refString="Lin, C. Y., Huang, Z., Wen, W., Wu, A., Wang, C., Niu, L., 2015. Enhancing protein expression in HEK- 293 cells by lowering culture temperature. PLoS One 10 (4), e 0123562. https: // doi. org / 10.1371 / journal. pone. 0123562." type="journal article" year="2015">Lin et al., 2015</bibRefCitation>
). On the day of the electrophysiological recordings, the cells were washed with phosphate-buffered saline (Sigma-Aldrich), detached by using 10% StemPro Accutase (4 min at 30 °C; Gibco), re-suspended in extracellular solution, and maintained at 4 °C for 15 min. Cells used for automated patch-clamp measurements were kept in suspension for approximately 2 h.
</paragraph>
</subSection>
<subSection _generate="added" pageId="17" pageNumber="18" type="multiple">
<paragraph blockId="17.[100,637,1721,1740]" box="[100,637,1721,1740]" pageId="17" pageNumber="18">
<heading bold="true" box="[100,637,1721,1740]" fontSize="36" level="1" pageId="17" pageNumber="18" reason="1">
<emphasis bold="true" box="[100,637,1721,1740]" italics="true" pageId="17" pageNumber="18">4.3. Automated patch-clamp electrophysiology in CHO cells</emphasis>
</heading>
</paragraph>
<paragraph blockId="17.[100,771,1777,1992]" lastBlockId="17.[818,1488,1331,1797]" pageId="17" pageNumber="18">
Electrophysiological measurements were performed by using the whole-cell configuration of the patch-clamp technique with an automated patch-clamp system (Patchliner Octo 
<emphasis bold="true" box="[533,544,1834,1853]" italics="true" pageId="17" pageNumber="18">®</emphasis>
, Nanion Technologies, Munich, 
<collectingCountry box="[189,277,1861,1880]" name="Germany" pageId="17" pageNumber="18">Germany</collectingCountry>
) in accordance with the manufacturer's standard procedures. The Patchliner Octo 
<emphasis bold="true" box="[403,414,1890,1909]" italics="true" pageId="17" pageNumber="18">®</emphasis>
is equipped with two EPC-10 Quadro patch-clamp amplifiers (HEKA Elektronik, Lambrecht, 
<collectingCountry box="[630,718,1917,1936]" name="Germany" pageId="17" pageNumber="18">Germany</collectingCountry>
) permitting electrophysiological recordings of up to eight cells simultaneously. The external solution contained 140 mM NaCl, 4 mM KCl, 1 mM MgCl 
<subScript attach="right" box="[927,936,1340,1352]" fontSize="5" pageId="17" pageNumber="18">2</subScript>
, 2 mM CaCl 
<subScript attach="left" box="[1053,1062,1340,1352]" fontSize="5" pageId="17" pageNumber="18">2</subScript>
, 5 mM glucose, and 10 mM HEPES, adjusted to pH 7.4 with NaOH (298 mOsmol). The internal solution contained 50 mM KCl, 60 mM kF, 10 mM NaCl, 20 mM EGTA, and 10 mM HEPES, adjusted to pH 7.2 with KOH (285 mOsmol). A seal-enhancer solution containing 80 mM NaCl, 3 mM KCl, 10 mM MgCl 
<subScript attach="left" box="[1289,1298,1452,1464]" fontSize="5" pageId="17" pageNumber="18">2</subScript>
, 35 mM CaCl 
<subScript attach="left" box="[1429,1438,1452,1464]" fontSize="5" pageId="17" pageNumber="18">2</subScript>
, and 10 mM HEPES (pH 7.4 adjusted with HCl, 298 mOsmol) was used and replaced with the external solution once the whole-cell configuration was established. The solutions were filtered through a 0.22-μM membrane (Merck Millipore, Burlington, MA, 
<collectingCountry box="[1201,1244,1554,1573]" name="United States of America" pageId="17" pageNumber="18">USA</collectingCountry>
) and maintained for up to 6 months at room temperature (24 °C).
</paragraph>
<paragraph blockId="17.[818,1488,1331,1797]" pageId="17" pageNumber="18">Data acquisition was performed with the PatchControlHT software (Nanion Technologies, ver. 2.01.31) in combination with the Patchmaster software (HEKA Elektronik, ver. 2 × 90.4 beta). For ligand-gated channel activation, 5 μL of a given ligand was applied at a speed of 114 μL/s, directly followed by 120 μL of external solution for washout. Data were recorded at a holding potential of −70 mV and a sampling rate of 20 kHz and filtered at 3 kHz.</paragraph>
</subSection>
<subSection _generate="added" lastPageId="18" lastPageNumber="19" pageId="17" pageNumber="18" type="multiple">
<paragraph blockId="17.[818,1199,1860,1880]" box="[818,1199,1860,1880]" pageId="17" pageNumber="18">
<heading bold="true" box="[818,1199,1860,1880]" fontSize="36" level="1" pageId="17" pageNumber="18" reason="1">
<emphasis bold="true" box="[818,1199,1860,1880]" italics="true" pageId="17" pageNumber="18">4.4. Data analysis and acceptance criteria</emphasis>
</heading>
</paragraph>
<paragraph blockId="17.[818,1487,1916,1992]" lastBlockId="18.[100,770,1163,1322]" lastPageId="18" lastPageNumber="19" pageId="17" pageNumber="18">
Data were analyzed by using Patchmaster and corrected for leak current. The data acceptance criteria were as follows: seal resistance,&gt; 100 M 
<emphasis bold="true" box="[1004,1020,1972,1991]" pageId="17" pageNumber="18">Ώ</emphasis>
; seal resistance loss variation, &lt;50%; access resistance, &lt;20 M 
<emphasis bold="true" box="[275,291,1163,1182]" pageId="18" pageNumber="19">Ώ</emphasis>
; and minimum current amplitude elicited by 
<subScript attach="both" box="[100,199,1191,1212]" fontSize="5" pageId="18" pageNumber="19">ECmaxACh</subScript>
,&gt; 100 pA. Offline data analysis was performed in Apache OpenOffice™ (Microsoft, Redmond, WA, 
<collectingCountry box="[506,549,1219,1238]" name="United States of America" pageId="18" pageNumber="19">USA</collectingCountry>
; ver. 4.1.2). Data are presented as mean ± SD. All experiments were performed at room temperature (24 °C).
</paragraph>
<caption ID-DOI="http://doi.org/10.5281/zenodo.8194195" ID-Zenodo-Dep="8194195" httpUri="https://zenodo.org/record/8194195/files/figure.png" pageId="18" pageNumber="19" startId="18.[100,130,818,835]" targetBox="[107,755,154,793]" targetPageId="18" targetType="figure">
<paragraph blockId="18.[100,770,818,1116]" pageId="18" pageNumber="19">
<emphasis bold="true" box="[100,159,818,835]" pageId="18" pageNumber="19">Fig. 4.</emphasis>
Concentration–response curves were obtained by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV from CHO cells stably expressing human α4β2 (continuous black lines) or human α7 (dotted grey lines) nAChRs. The lines represent the fits to the Hill equation for nicotine (
<emphasis bold="true" box="[183,194,920,937]" pageId="18" pageNumber="19">1</emphasis>
) (circles symbols), anabasine (
<emphasis bold="true" box="[461,483,920,937]" pageId="18" pageNumber="19">12</emphasis>
) (triangles symbols), nornicotine (
<emphasis bold="true" box="[107,118,946,962]" pageId="18" pageNumber="19">7</emphasis>
) (squared symbols), and S-anatabine (
<emphasis bold="true" box="[474,496,946,963]" pageId="18" pageNumber="19">16</emphasis>
) (diamonds symbols). The fit parameters are presented (Table 1). The averaged normalized current response is plotted as a function of the maximal current to ACh (
<subScript attach="both" box="[590,664,996,1016]" fontSize="5" pageId="18" pageNumber="19">ImaxACh</subScript>
). Two backgrounds highlight the concentration range of the tobacco alkaloids levels measured in human plasma (grey background with diagonal lines) and in human cerebrospinal fluid (grey background with horizontal lines). Data are presented as mean ± SD.
</paragraph>
</caption>
<paragraph blockId="18.[100,770,1163,1322]" box="[133,671,1303,1322]" pageId="18" pageNumber="19">Agonistic effects (percent activation) were calculated as:</paragraph>
<paragraph blockId="18.[100,268,1341,1363]" box="[100,268,1341,1363]" pageId="18" pageNumber="19">(I ago/I max ACh)100,</paragraph>
<paragraph blockId="18.[100,770,1387,1490]" pageId="18" pageNumber="19">
where 
<subScript attach="left" box="[164,196,1387,1408]" fontSize="5" pageId="18" pageNumber="19">Iago</subScript>
is the agonist-induced current of the tobacco alkaloids at 3.7 or 33.3 μM.
</paragraph>
<paragraph blockId="18.[100,770,1387,1490]" pageId="18" pageNumber="19">PAM effects of the alkaloids (in percent) on the channels were calculated as:</paragraph>
<paragraph blockId="18.[100,350,1509,1531]" box="[100,350,1509,1531]" pageId="18" pageNumber="19">(I ago+EC20ACh/I EC20ACh)100,</paragraph>
<paragraph blockId="18.[100,770,1554,1683]" pageId="18" pageNumber="19">
where 
<subScript attach="left" box="[164,279,1555,1575]" fontSize="5" pageId="18" pageNumber="19">Iago+EC20ACh</subScript>
was the ACh EC 
<subScript attach="left" box="[432,450,1563,1575]" fontSize="5" pageId="18" pageNumber="19">20</subScript>
-elicited current in the presence of 3.7 or 33.3 μM of the tobacco alkaloids.
</paragraph>
<paragraph blockId="18.[100,770,1554,1683]" lastBlockId="18.[100,391,1704,1727]" pageId="18" pageNumber="19">
Igor Pro (ver. 6.2.2.2, Lake Oswego, OR, 
<collectingCountry box="[532,575,1610,1629]" name="United States of America" pageId="18" pageNumber="19">USA</collectingCountry>
) was used for assessing the concentration-response curves by fitting with the following Hill equation: I max/([1 + (Ago EC50/Ago)nH]),
</paragraph>
<paragraph blockId="18.[100,770,1749,1824]" pageId="18" pageNumber="19">
where 
<subScript attach="left" box="[166,203,1749,1770]" fontSize="5" pageId="18" pageNumber="19">Imax</subScript>
is the maximal current, Ago EC 
<subScript attach="left" box="[511,529,1758,1770]" fontSize="5" pageId="18" pageNumber="19">50</subScript>
is the agonist concentration producing half-maximal activation, Ago is the agonist concentration, and nH is the Hill coefficient.
</paragraph>
</subSection>
<subSection _generate="added" pageId="18" pageNumber="19" type="multiple">
<paragraph blockId="18.[100,756,1860,1880]" box="[100,756,1860,1880]" pageId="18" pageNumber="19">
<heading bold="true" box="[100,756,1860,1880]" centered="true" fontSize="36" level="1" pageId="18" pageNumber="19" reason="1">
<emphasis bold="true" box="[100,756,1860,1880]" italics="true" pageId="18" pageNumber="19">4.5. Automated two-electrode voltage-clamp electrophysiological assay in</emphasis>
</heading>
</paragraph>
<paragraph blockId="18.[100,247,1889,1908]" box="[100,247,1889,1908]" pageId="18" pageNumber="19">
<heading box="[100,247,1889,1908]" fontSize="8" level="3" pageId="18" pageNumber="19" reason="8">
<taxonomicName _evidence="catalog+fontStyle" _step="styledSpecies" box="[100,247,1889,1908]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="18" pageNumber="19" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[100,247,1889,1908]" italics="true" pageId="18" pageNumber="19">Xenopus oocytes</emphasis>
</taxonomicName>
</heading>
</paragraph>
<paragraph blockId="18.[100,769,1944,1992]" lastBlockId="18.[818,1488,159,792]" pageId="18" pageNumber="19">
All experiments were conducted with human nAChRs expressed in 
<taxonomicName _evidence="document" _step="document" box="[100,260,1973,1992]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="18" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[100,174,1973,1992]" italics="true" pageId="18" pageNumber="19">Xenopus</emphasis>
oocytes
</taxonomicName>
. Currents evoked by ACh and other compounds of interest were recorded by using an automated two-electrode voltage-clamp system (HiClamp, Multichannel Systems, Reutlingen, 
<collectingCountry box="[1387,1478,187,206]" name="Germany" pageId="18" pageNumber="19">Germany</collectingCountry>
). 
<taxonomicName _evidence="document" _step="document" box="[818,967,215,234]" class="Insecta" family="Curculionidae" genus="Xenopus" kingdom="Animalia" order="Coleoptera" pageId="18" pageNumber="20" phylum="Arthropoda" rank="species" species="oocytes">
<emphasis bold="true" box="[818,892,215,234]" italics="true" pageId="18" pageNumber="19">Xenopus</emphasis>
oocytes
</taxonomicName>
were prepared and injected using standard procedures. Defoliculated oocytes (Ecocyte Bioscience, Castrop-Rauxel, 
<collectingCountry box="[1393,1481,243,262]" name="Germany" pageId="18" pageNumber="19">Germany</collectingCountry>
) were injected with 
<quantity box="[999,1078,271,290]" metricMagnitude="-13" metricUnit="kg" metricValue="5.5" metricValueMax="10.0" metricValueMin="1.0" pageId="18" pageNumber="19" unit="ng" value="0.55" valueMax="1.0" valueMin="0.1">0.1–1 ng</quantity>
of cRNA per oocyte by using an automated injector (Roboinject, Multi Channel Systems). For all experiments conducted with subunits, the oocytes were injected at a 1:1 cRNA ratio such that both forms would be expressed at equal levels (Supplementary 
<figureCitation box="[976,1031,382,401]" captionStart="Fig" captionStartId="11.[100,130,694,711]" captionTargetBox="[265,1323,153,670]" captionTargetId="figure-886@11.[263,1324,152,671]" captionTargetPageId="11" captionText="Fig. 3. Sequential applications of brief ACh pulses are plotted as a function of time for three ACh concentrations. (a) EC20 = 0.4 μM (circles), EC50 = 1.2 μM (squares), EC90 = 11.1 μM (triangles) for human α4β2 receptors. (b) EC20 = 33.3 μM (circles), EC60 = 300 μM (squares), EC90 = 900 μM (triangles) for human α7 receptors. Experiments were performed by using the whole-cell mode of the patch-clamp technique at a holding potential of −70 mV in CHO cells stably expressing the human α4β2 and α7 nAChRs. EC, effective concentration. Data are presented as mean ± SD." figureDoi="http://doi.org/10.5281/zenodo.8194193" httpUri="https://zenodo.org/record/8194193/files/figure.png" pageId="18" pageNumber="19">Fig. 3</figureCitation>
). All recordings were performed at 18 ± 4 °C, and the cells were perfused with OR2 medium containing 88.5 mM NaCl, 2.5 mM KCl, 1.5 mM HEPES, and 2.5 mM CaCl 
<subScript attach="left" box="[1335,1344,447,459]" fontSize="5" pageId="18" pageNumber="19">2</subScript>
(pH 7.4). The cells were held at −80 mV, and data were captured at 100 Hz, filtered at 20 Hz, and analyzed by using the HiClamp data acquisition and analysis software running under MATLAB (MathWorks Inc., Natick, MA, 
<collectingCountry box="[875,921,550,569]" name="United States of America" pageId="18" pageNumber="19">USA</collectingCountry>
). Statistical analysis was performed by using Prism (GraphPad, La Jolla, CA, 
<collectingCountry box="[1052,1095,578,597]" name="United States of America" pageId="18" pageNumber="19">USA</collectingCountry>
; ver. 5) and Excel (Microsoft, ver. 14.7.3). Selected tobacco alkaloids were tested on oocytes expressing human α7, α4β2, and α3β4 nAChRs. Cells expressing significant current evoked by a brief ACh pulse (10 μM) were tested for their response to tobacco alkaloids (concentrations, 3.7 and 33.3 μM) by using the screening protocol in order to determine the agonistic effects of the compounds. The percentage of agonism was assessed by comparing the response to the reference ACh peak current.
</paragraph>
<paragraph blockId="18.[818,901,828,847]" box="[818,901,828,847]" pageId="18" pageNumber="19">
<emphasis bold="true" box="[818,901,828,847]" pageId="18" pageNumber="19">Funding</emphasis>
</paragraph>
<paragraph blockId="18.[818,1487,884,931]" pageId="18" pageNumber="19">Philip Morris International is the sole source of funding and sponsor of this research.</paragraph>
</subSection>
<subSection _generate="added" pageId="18" pageNumber="19" type="acknowledgments">
<paragraph blockId="18.[818,1004,968,987]" box="[818,1004,968,987]" pageId="18" pageNumber="19">
<heading bold="true" box="[818,1004,968,987]" fontSize="36" level="1" pageId="18" pageNumber="19" reason="2">
<emphasis bold="true" box="[818,1004,968,987]" pageId="18" pageNumber="19">Acknowledgments</emphasis>
</heading>
</paragraph>
<paragraph blockId="18.[818,1487,1024,1071]" pageId="18" pageNumber="19">We would like to thank Marco Van der Toorn and Yueh-Wen Lin for compound preparation and Dean Meyer for manuscript review.</paragraph>
</subSection>
<subSection _generate="added" pageId="18" pageNumber="19" type="multiple">
<paragraph blockId="18.[818,1157,1107,1127]" box="[818,1157,1107,1127]" pageId="18" pageNumber="19">
<heading bold="true" box="[818,1157,1107,1127]" fontSize="36" level="1" pageId="18" pageNumber="19" reason="2">
<emphasis bold="true" box="[818,1157,1107,1127]" pageId="18" pageNumber="19">Appendix A. Supplementary data</emphasis>
</heading>
</paragraph>
<paragraph blockId="18.[818,1487,1163,1211]" pageId="18" pageNumber="19">Supplementary data to this article can be found online at https:// doi.org/10.1016/j.phytochem.2019.112187.</paragraph>
</subSection>
<subSection _generate="added" lastPageId="19" lastPageNumber="20" pageId="18" pageNumber="19" type="reference_group">
<paragraph blockId="18.[818,928,1247,1266]" box="[818,928,1247,1266]" pageId="18" pageNumber="19">
<heading bold="true" box="[818,928,1247,1266]" fontSize="36" level="1" pageId="18" pageNumber="19" reason="2">
<emphasis bold="true" box="[818,928,1247,1266]" pageId="18" pageNumber="19">References</emphasis>
</heading>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7425" type="journal article">
<author box="[818,918,1306,1321]" case="TC" fns="I" in="I.T." ins="D" ln="Baldwin" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Baldwin, I.T.</author>
, 
<author box="[925,1034,1306,1321]" case="TC" fns="I" in="R." ins="D" ln="Halitschke" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Halitschke, R.</author>
, 
<author box="[1041,1124,1306,1321]" case="TC" fns="I" in="A." ins="D" ln="Kessler" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Kessler, A.</author>
, 
<author box="[1131,1223,1306,1321]" case="TC" fns="I" in="U." ins="D" ln="Schittko" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Schittko, U.</author>
, 
<year box="[1230,1271,1307,1321]" pageId="18" pageNumber="19">2001</year>
. 
<title jopScore="0.52709997" pageId="18" pageNumber="19">Merging molecular and ecological approaches in plant–insect interactions</title>
. 
<journalOrPublisher box="[1229,1396,1328,1342]" jopScore="1.0486401" pageId="18" pageNumber="19">Curr. Opin. Plant Biol.</journalOrPublisher>
<part box="[1398,1409,1328,1342]" pageId="18" pageNumber="19" type="volume">4</part>
, 
<pagination box="[1416,1484,1328,1342]" pageId="18" pageNumber="19" type="pagination">351–358</pagination>
. 
<DOI box="[849,1227,1349,1364]" pageId="18" pageNumber="19">https://doi.org/10.1016/S1369-5266(00)00184-9</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7493" type="book chapter">
<author box="[818,860,1370,1384]" fns="*" inm="true" npo="*" pageId="18" pageNumber="19">Blum</author>
, 
<author box="[866,939,1370,1384]" case="TC" fns="I" in="P." ins="D" ln="Angela" lnc="TC" npo="LnIn" pageId="18" pageNumber="19">Angela P.</author>
, 
<author box="[946,993,1370,1384]" fns="*" inm="true" npo="*" pageId="18" pageNumber="19">Lester</author>
, 
<author box="[1000,1070,1370,1384]" case="TC" fns="I" in="A." ins="D" ln="Henry" lnc="TC" npo="LnIn" pageId="18" pageNumber="19">Henry A.</author>
, 
<author box="[1075,1156,1370,1384]" fns="*" inm="true" npo="*" pageId="18" pageNumber="19">Dougherty</author>
, 
<author box="[1163,1239,1370,1384]" case="TC" fns="I" in="A." ins="D" ln="Dennis" lnc="TC" npo="LnIn" pageId="18" pageNumber="19">Dennis A.</author>
, 
<year box="[1244,1285,1370,1384]" pageId="18" pageNumber="19">2010</year>
. 
<title jopScore="0.046562273" pageId="18" pageNumber="19" type="_" typeScore="58">Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH</title>
. 
<journalOrPublisher box="[1124,1279,1413,1427]" jopScore="1.1549833" pageId="18" pageNumber="19">Proc. Natl. Acad. Sci</journalOrPublisher>
. 
<pagination box="[1286,1392,1413,1427]" pageId="18" pageNumber="19" type="pagination">13206–13211</pagination>
. 
<DOI pageId="18" pageNumber="19">https://doi. org/10.1073/pnas.1007140107</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7561" type="book chapter">
<author box="[818,910,1455,1469]" case="TC" fns="I" in="C.A." ins="D" ln="Briggs" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Briggs, C.A.</author>
, 
<author box="[917,1032,1455,1469]" case="TC" fns="I" in="D.G." ins="D" ln="Mckenna" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Mckenna, D.G.</author>
, Piattina-kaplan, M., 
<year box="[1194,1235,1455,1469]" pageId="18" pageNumber="19">1995</year>
. 
<title jopScore="0.033362553" pageId="18" pageNumber="19" type="_" typeScore="58">Human α 7 nicotinic acetylcholine receptor responses to novel ligands</title>
. 
<journalOrPublisher box="[1161,1314,1476,1490]" jopScore="0.0025663502" pageId="18" pageNumber="19">Neuropharmacology</journalOrPublisher>
<pagination box="[1320,1389,1476,1490]" pageId="18" pageNumber="19" type="pagination">583–590</pagination>
. 
<DOI pageId="18" pageNumber="19">https://doi. org/10.1016/0028-3908(95)00028-5</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7617" type="journal article">
<author box="[818,903,1519,1533]" case="TC" fns="I" in="B." ins="D" ln="Buisson" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Buisson, B.</author>
, 
<author box="[910,1061,1519,1533]" case="TC" fns="I" in="M." ins="D" ln="Gopalakrishnan" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Gopalakrishnan, M.</author>
, 
<author box="[1068,1165,1519,1533]" case="TC" fns="I" in="S.P." ins="D" ln="Arneric" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Arneric, S.P.</author>
, 
<author box="[1173,1274,1519,1533]" case="TC" fns="I" in="J.P." ins="D" ln="Sullivan" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Sullivan, J.P.</author>
, 
<author box="[1281,1377,1519,1533]" case="TC" fns="I" in="D." ins="D" ln="Bertrand" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Bertrand, D.</author>
, 
<year box="[1384,1425,1519,1533]" pageId="18" pageNumber="19">1996</year>
. 
<title jopScore="0.03065769" pageId="18" pageNumber="19">Human α4β2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J</title>
. 
<journalOrPublisher box="[919,992,1562,1576]" jopScore="0.0015328845" pageId="18" pageNumber="19">Neurosci.</journalOrPublisher>
<part box="[996,1017,1561,1575]" pageId="18" pageNumber="19" type="volume">16</part>
, 
<pagination box="[1025,1046,1562,1576]" pageId="18" pageNumber="19" type="pagination">24</pagination>
. 
<DOI box="[1055,1482,1561,1576]" pageId="18" pageNumber="19">https://doi.org/10.1523/JNEUROSCI.16-24-07880.1996</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7691" type="journal article">
<author box="[818,912,1583,1597]" case="TC" fns="I" in="R.F." ins="D" ln="Burton" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Burton, R.F.</author>
, 
<year box="[919,960,1583,1597]" pageId="18" pageNumber="19">1983</year>
. 
<title pageId="18" pageNumber="19">The composition of animal cells: solutes contributing to osmotic pressure and charge balance</title>
. 
<journalOrPublisher box="[1075,1281,1604,1618]" pageId="18" pageNumber="19">Comp. Biochem. Physiol. B</journalOrPublisher>
<part box="[1286,1305,1604,1618]" pageId="18" pageNumber="19" type="volume">76</part>
(
<part box="[1318,1329,1604,1618]" pageId="18" pageNumber="19" type="issue">4</part>
), 
<pagination box="[1344,1413,1604,1618]" pageId="18" pageNumber="19" type="pagination">663–671</pagination>
. 
<DOI pageId="18" pageNumber="19">https:// doi.org/10.1016/0305-0491(83)90375-9</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7750" type="journal article">
<author box="[818,921,1646,1661]" case="TC" fns="I" in="N.D." ins="D" ln="Cosford" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Cosford, N.D.</author>
, 
<author box="[927,1015,1646,1661]" case="TC" fns="I" in="L." ins="D" ln="Bleicher" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Bleicher, L.</author>
, 
<author box="[1021,1122,1646,1661]" case="TC" fns="I" in="J.M." ins="D" ln="Vernier" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Vernier, J.M.</author>
, 
<author box="[1129,1274,1646,1661]" case="TC" fns="I" in="L." ins="D" ln="Chavez-Noriega" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Chavez-Noriega, L.</author>
, 
<author box="[1280,1350,1647,1661]" case="TC" fns="I" in="T.S." ins="D" ln="Rao" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Rao, T.S.</author>
, 
<author box="[1356,1442,1646,1661]" case="TC" fns="I" in="R.S." ins="D" ln="Siegel" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Siegel, R.S.</author>
, 
<author case="TC" fns="I" in="C." ins="D" ln="Suto" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Suto, C.</author>
, 
<author box="[875,984,1668,1682]" case="TC" fns="I" in="M." ins="D" ln="Washburn" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Washburn, M.</author>
, 
<author box="[991,1078,1668,1682]" case="TC" fns="I" in="G.K." ins="D" ln="Lloyd" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Lloyd, G.K.</author>
, 
<author box="[1085,1201,1668,1682]" case="TC" fns="I" in="I.A." ins="D" ln="McDonald" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">McDonald, I.A.</author>
, 
<year box="[1208,1249,1668,1682]" pageId="18" pageNumber="19">2000</year>
. 
<title jopScore="0.1667799" pageId="18" pageNumber="19">Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist</title>
. 
<journalOrPublisher box="[1160,1301,1710,1724]" jopScore="2.4464285" pageId="18" pageNumber="19">Pharm. Acta Helv.</journalOrPublisher>
<part box="[1305,1324,1710,1724]" pageId="18" pageNumber="19" type="volume">74</part>
(2– 
<part box="[1357,1366,1710,1724]" pageId="18" pageNumber="19" type="issue">3</part>
), 
<pagination box="[1380,1448,1710,1724]" pageId="18" pageNumber="19" type="pagination">125–130</pagination>
. 
<DOI box="[849,1226,1731,1746]" pageId="18" pageNumber="19">https://doi.org/10.1016/S0165-7208(00)80008-2</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7877" type="journal article">
<author box="[818,927,1753,1767]" case="TC" fns="I" in="V." ins="D" ln="Echeverria" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Echeverria, V.</author>
, 
<year box="[934,975,1753,1767]" pageId="18" pageNumber="19">2012</year>
. 
<title jopScore="0.12213705" pageId="18" pageNumber="19">Cotinine: beyond that expected, more than a biomarker of tobacco consumption</title>
. 
<journalOrPublisher box="[957,1094,1774,1788]" jopScore="1.25" pageId="18" pageNumber="19">Front. Pharmacol.</journalOrPublisher>
<part box="[1098,1109,1774,1788]" pageId="18" pageNumber="19" type="volume">3</part>
, 
<pagination box="[1117,1147,1774,1788]" pageId="18" pageNumber="19" type="pagination">1–9</pagination>
. 
<DOI box="[1155,1482,1774,1788]" pageId="18" pageNumber="19">https://doi.org/10.3389/fphar.2012.00173</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7921" type="journal article">
<author box="[818,927,1795,1810]" case="TC" fns="I" in="V." ins="D" ln="Echeverria" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Echeverria, V.</author>
, 
<author box="[933,1032,1795,1809]" case="TC" fns="I" in="J.A." ins="D" ln="Grizzell" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Grizzell, J.A.</author>
, GE, Barreto, 
<year box="[1135,1176,1795,1809]" pageId="18" pageNumber="19">2016</year>
. 
<title jopScore="2.1067066" pageId="18" pageNumber="19" type="_" typeScore="84">Neuroinflammation: a therapeutic target of cotinine for the treatment of psychiatric disorders? Curr. Pharmaceut</title>
. 
<journalOrPublisher box="[1407,1441,1817,1831]" jopScore="0.28259173" pageId="18" pageNumber="19">Des.</journalOrPublisher>
<part box="[1445,1466,1817,1831]" pageId="18" pageNumber="19" type="volume">22</part>
, 
<pagination box="[849,937,1838,1852]" pageId="18" pageNumber="19" type="pagination">1324–1333</pagination>
. 
<DOI box="[945,1366,1838,1853]" pageId="18" pageNumber="19">
https://doi.org/10.2174/ 
<uuid box="[1126,1366,1838,1853]" pageId="18" pageNumber="19">138161282210160304112511</uuid>
</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref7976" type="journal article">
<author box="[818,927,1859,1873]" case="TC" fns="I" in="R.A." ins="D" ln="Glennon" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Glennon, R.A.</author>
, 
<author box="[934,1012,1859,1873]" case="TC" fns="I" in="M." ins="D" ln="Dukat" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Dukat, M.</author>
, 
<year box="[1019,1060,1859,1873]" pageId="18" pageNumber="19">2004</year>
. 
<title box="[1068,1409,1859,1873]" pageId="18" pageNumber="19">α4β2 nACh receptor pharmacophore models</title>
. 
<journalOrPublisher pageId="18" pageNumber="19">Bioorg. Med. Chem. Lett</journalOrPublisher>
<part box="[981,1002,1880,1894]" pageId="18" pageNumber="19" type="volume">14</part>
, 
<pagination box="[1010,1098,1880,1894]" pageId="18" pageNumber="19" type="pagination">1841–1844</pagination>
. 
<DOI box="[1106,1444,1880,1895]" pageId="18" pageNumber="19">https://doi.org/10.1016/j.bmcl.2003.07.035</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" pageId="18" pageNumber="19" refId="ref8027" type="journal article">
<author box="[818,925,1902,1916]" case="TC" fns="I" in="R.A." ins="D" ln="Glennon" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Glennon, R.A.</author>
, 
<author box="[931,1022,1902,1916]" case="TC" fns="I" in="A." ins="D" ln="Maarouf" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Maarouf, A.</author>
, 
<author box="[1028,1104,1902,1916]" case="TC" fns="I" in="S." ins="D" ln="Fahmy" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Fahmy, S.</author>
, 
<author box="[1110,1188,1902,1916]" case="TC" fns="I" in="B." ins="D" ln="Martin" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Martin, B.</author>
, 
<author box="[1194,1247,1902,1916]" case="TC" fns="I" in="F." ins="D" ln="Fan" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Fan, F.</author>
, 
<author box="[1253,1331,1902,1916]" case="TC" fns="I" in="M." ins="D" ln="Yousif" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Yousif, M.</author>
, 
<author box="[1337,1432,1902,1916]" case="TC" fns="I" in="R.M." ins="D" ln="Shafik" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Shafik, R.M.</author>
, 
<author case="TC" fns="I" in="M." ins="D" ln="Dukat" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Dukat, M.</author>
, 
<year box="[880,921,1923,1937]" pageId="18" pageNumber="19">1993</year>
. 
<title box="[928,1368,1923,1937]" pageId="18" pageNumber="19">Structure-activity relationships of simple nicotine analogs</title>
. 
<journalOrPublisher pageId="18" pageNumber="19">Med. Chem. Res.</journalOrPublisher>
<part box="[886,897,1944,1958]" pageId="18" pageNumber="19" type="volume">2</part>
, 
<pagination box="[906,974,1944,1958]" pageId="18" pageNumber="19" type="pagination">546–551</pagination>
. 
<publicationUrl box="[982,1274,1944,1958]" pageId="18" pageNumber="19">https://ci.nii.ac.jp/naid/10011030393</publicationUrl>
.
</bibRef>
</paragraph>
<paragraph blockId="18.[818,1489,1306,1980]" lastBlockId="19.[100,771,163,1538]" lastPageId="19" lastPageNumber="20" pageId="18" pageNumber="19">
<bibRef _evidence="authorList" lastPageId="19" lastPageNumber="20" pageId="18" pageNumber="19" refId="ref8107" type="journal article">
<author box="[818,907,1965,1979]" case="TC" fns="I" in="A." ins="D" ln="Graham" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Graham, A.</author>
, 
<author box="[914,998,1965,1979]" case="TC" fns="I" in="J.A." ins="D" ln="Court" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Court, J.A.</author>
, 
<author box="[1005,1031,1965,1979]" fns="*" inm="true" npo="*" pageId="18" pageNumber="19">CM</author>
<author box="[1035,1145,1965,1980]" case="TC" fns="I" in="E" ins="U" ln="Martin-Ruiz" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Martin-Ruiz, E</author>
<author box="[1150,1191,1966,1980]" fns="*" inm="true" npo="*" pageId="18" pageNumber="19">Jaros</author>
, 
<author box="[1200,1269,1966,1980]" case="TC" fns="I" in="R." ins="D" ln="Perry" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Perry, R.</author>
, 
<author box="[1276,1369,1965,1979]" case="TC" fns="I" in="S.G." ins="D" ln="Volsen" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Volsen, S.G.</author>
, 
<author box="[1376,1437,1965,1980]" case="TC" fns="I" in="S." ins="D" ln="Bose" lnc="TC" npo="LnFn" pageId="18" pageNumber="19">Bose, S.</author>
, et al., 
<year box="[132,173,163,177]" pageId="19" pageNumber="20">2002</year>
. 
<title pageId="19" pageNumber="20">Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum</title>
. 
<journalOrPublisher box="[304,404,184,198]" pageId="19" pageNumber="20">Neuroscience</journalOrPublisher>
<part box="[410,439,184,198]" pageId="19" pageNumber="20" type="volume">113</part>
(
<part box="[451,461,184,198]" pageId="19" pageNumber="20" type="issue">3</part>
), 
<pagination box="[477,546,184,198]" pageId="19" pageNumber="20" type="pagination">493–507</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1016/ S0306-4522(02)00223-3</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8189" type="book chapter">
<author box="[100,158,226,240]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Grando</author>
, 
<author box="[166,238,226,241]" case="TC" fns="I" in="A." ins="D" ln="Sergei" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Sergei A.</author>
, 
<year box="[245,286,227,241]" pageId="19" pageNumber="20">2014</year>
. 
<title box="[294,551,226,241]" jopScore="0.26248938" pageId="19" pageNumber="20" type="_" typeScore="58">Connections of nicotine to cancer</title>
. 
<journalOrPublisher box="[558,686,227,241]" jopScore="0.979798" pageId="19" pageNumber="20">Nat. Rev. Cancer</journalOrPublisher>
<pagination box="[692,760,227,241]" pageId="19" pageNumber="20" type="pagination">419–429</pagination>
. 
<DOI box="[132,386,248,263]" pageId="19" pageNumber="20">https://doi.org/10.1038/nrc3725</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8224" type="journal article">
<author box="[100,175,269,283]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Hamouda</author>
, 
<author box="[184,261,269,283]" case="TC" fns="I" in="K." ins="D" ln="Ayman" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Ayman K.</author>
, 
<author box="[268,362,269,283]" case="TC" fn="Farah" fnc="TC" fns="N" ln="Deba" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Deba, Farah</author>
, 
<author box="[371,477,269,283]" case="TC" fn="Ze-Jun" fnc="TC" fns="N" ln="Wang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wang, Ze-Jun</author>
, 
<author box="[486,536,269,283]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Cohen</author>
, 
<author box="[544,637,269,283]" case="TC" fns="I" in="B." ins="D" ln="Jonathan" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Jonathan B.</author>
, 
<year box="[644,685,269,283]" pageId="19" pageNumber="20">2016</year>
. 
<title jopScore="0.18149266" pageId="19" pageNumber="20" type="_" typeScore="84">Photolabeling a nicotinic acetylcholine receptor (nAChR) with an (α4)3(β2)2 nAChR-selective positive allosteric modulator</title>
. 
<journalOrPublisher box="[425,550,312,326]" jopScore="1.402174" pageId="19" pageNumber="20">Mol. Pharmacol.</journalOrPublisher>
<part box="[552,571,312,326]" pageId="19" pageNumber="20" type="volume">89</part>
(
<part box="[582,592,311,325]" pageId="19" pageNumber="20" type="issue">5</part>
), 
<pagination box="[607,675,311,325]" pageId="19" pageNumber="20" type="pagination">575–584</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi. org/10.1124/mol.116.103341</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8297" type="journal article">
<author box="[100,206,354,368]" case="TC" fns="I" in="J.R." ins="D" ln="Holtman" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Holtman, J.R.</author>
, 
<author box="[213,308,354,368]" case="TC" fns="I" in="P.A." ins="D" ln="Crooks" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Crooks, P.A.</author>
, 
<author box="[314,405,354,368]" case="TC" fns="I" in="L." ins="D" ln="Dwoskin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Dwoskin, L.</author>
, 
<author box="[411,491,354,368]" case="TC" fns="I" in="E.P." ins="D" ln="Wala" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wala, E.P.</author>
, 
<year box="[497,538,354,368]" pageId="19" pageNumber="20">2010</year>
. 
<title jopScore="0.08487772" pageId="19" pageNumber="20">Nornicotine for the Treatment of Pain</title>
. 
<journalOrPublisher box="[196,282,375,390]" jopScore="0.31465518" pageId="19" pageNumber="20">USA Patent</journalOrPublisher>
<part box="[288,395,375,389]" pageId="19" pageNumber="20" type="volume">20100216847</part>
, August 
<pagination box="[462,481,375,389]" pageId="19" pageNumber="20" type="pagination">26</pagination>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8339" type="journal article">
<author box="[100,142,397,411]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Hone</author>
, 
<author box="[150,202,397,411]" case="TC" fns="I" in="J." ins="D" ln="Arik" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Arik J.</author>
, 
<author box="[211,369,397,411]" case="TC" fns="I" in="J." ins="D" ln="Michael McIntosh" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Michael McIntosh, J.</author>
, Rueda-Ruzafa, Lola, Passas, Juan, de Castro-Guerín, Cristina, Blázq, Jesús, González-Enguita, Carmen, Albillos, Almudena, 
<year box="[669,710,418,432]" pageId="19" pageNumber="20">2017</year>
. 
<title jopScore="0.069589175" pageId="19" pageNumber="20" type="_" typeScore="84">Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells. J</title>
. 
<journalOrPublisher box="[543,636,460,474]" jopScore="0.0079657715" pageId="19" pageNumber="20">Neurochem.</journalOrPublisher>
<part box="[640,669,460,474]" pageId="19" pageNumber="20" type="volume">140</part>
(
<part box="[682,690,460,474]" pageId="19" pageNumber="20" type="issue">1</part>
), 
<pagination box="[707,756,460,474]" pageId="19" pageNumber="20" type="pagination">37–52</pagination>
. 
<DOI box="[132,399,481,495]" pageId="19" pageNumber="20">https://doi.org/10.1111/jnc.13883</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8423" type="journal article">
<author box="[100,201,503,517]" case="TC" fns="I" in="J." ins="D" ln="Hukkanen" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Hukkanen, J.</author>
, 
<author box="[210,303,503,517]" fns="I" in="P." ins="D" ln="Jacob" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Jacob III, P.</author>
, 
<author box="[310,424,503,517]" case="TC" fns="I" in="N.L." ins="D" ln="Benowitz" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Benowitz, N.L.</author>
, 
<year box="[430,471,503,517]" pageId="19" pageNumber="20">2005</year>
. 
<title pageId="19" pageNumber="20">Metabolism and disposition kinetics of nicotine</title>
. 
<journalOrPublisher box="[203,329,524,538]" pageId="19" pageNumber="20">Pharmacol. Rev.</journalOrPublisher>
<part box="[333,354,524,538]" pageId="19" pageNumber="20" type="volume">79</part>
, 
<pagination box="[363,394,524,538]" pageId="19" pageNumber="20" type="pagination">115</pagination>
. 
<DOI box="[402,662,524,539]" pageId="19" pageNumber="20">https://doi.org/10.1124/pr.57.1.3</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" author="Jacob III, P L Yu &amp; Shulgin, A. T. &amp; Benowitz, N. L." journalOrPublisher="Am. J. Public Health" pageId="19" pageNumber="20" part="10224986" refId="ref8471" title="Minor tobacco alkaloids as biomarkers for tobacco use: comparison ofUsers of Cigarettes, smokeless tobacco, cigars, and pipes" type="journal volume" year="1999">
<author box="[100,229,545,560]" fns="I" in="P L Yu" ins="U" ln="Jacob" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Jacob III, P L Yu</author>
, 
<author box="[238,339,545,559]" case="TC" fns="I" in="A.T." ins="D" ln="Shulgin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Shulgin, A.T.</author>
, 
<author box="[347,461,545,560]" case="TC" fns="I" in="N.L." ins="D" ln="Benowitz" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Benowitz, N.L.</author>
, 
<year box="[468,509,545,559]" pageId="19" pageNumber="20">1999</year>
. 
<title pageId="19" pageNumber="20">Minor tobacco alkaloids as biomarkers for tobacco use: comparison ofUsers of Cigarettes, smokeless tobacco, cigars, and pipes</title>
. 
<journalOrPublisher box="[215,373,588,602]" pageId="19" pageNumber="20">Am. J. Public Health</journalOrPublisher>
731–736 PMID: 
<part box="[503,580,588,602]" pageId="19" pageNumber="20" type="volume">10224986</part>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8529" type="journal article">
<author box="[100,115,609,623]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Ji</author>
, 
<author box="[124,150,609,623]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Lin</author>
, Melkonian, Goar, Riveles, Karen, Tal, Prue, 
<year box="[493,534,609,623]" pageId="19" pageNumber="20">2002</year>
. 
<title jopScore="0.114900984" pageId="19" pageNumber="20" type="_" typeScore="84">Identification of pyridine compounds in cigarette smoke solution that inhibit growth of the chick chorioallantoic membrane</title>
. 
<journalOrPublisher box="[308,402,652,666]" jopScore="0.4817073" pageId="19" pageNumber="20">Toxicol. Sci.</journalOrPublisher>
<part box="[406,425,652,666]" pageId="19" pageNumber="20" type="volume">69</part>
(
<part box="[438,446,652,666]" pageId="19" pageNumber="20" type="issue">1</part>
), 
<pagination box="[464,532,651,665]" pageId="19" pageNumber="20" type="pagination">217–225</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1093/ toxsci/69.1.217</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8590" type="journal article">
<author box="[100,298,694,708]" case="TC" fn="Ben-Yehoshua" fnc="TC" fns="N" ln="Josefsberg" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Josefsberg, Ben-Yehoshua</author>
, 
<author box="[306,347,694,708]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Nava</author>
, Dekel, 
<year box="[408,449,694,708]" pageId="19" pageNumber="20">2002</year>
. 
<title jopScore="0.08521168" pageId="19" pageNumber="20" type="_" typeScore="84">Translational and post-translational modifications in meiosis of the mammalian oocyte</title>
. 
<journalOrPublisher box="[527,695,715,729]" jopScore="0.89556694" pageId="19" pageNumber="20">Mol. Cell. Endocrinol.</journalOrPublisher>
<part box="[698,728,715,729]" pageId="19" pageNumber="20" type="volume">187</part>
, 
<pagination box="[132,201,736,750]" pageId="19" pageNumber="20" type="pagination">161–171</pagination>
. 
<DOI box="[208,676,736,751]" pageId="19" pageNumber="20">https://doi.org/10.1016/S0303-7207(01)00688-8. Issues 1–2</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8648" type="journal article">
<author box="[100,170,758,772]" case="TC" fns="I" in="H." ins="D" ln="Khan" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Khan, H.</author>
, 
<author box="[177,241,758,772]" case="TC" fns="I" in="S." ins="D" ln="Patel" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Patel, S.</author>
, 
<author box="[250,344,758,772]" case="TC" fns="I" in="M.S." ins="D" ln="Kamal" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kamal, M.S.</author>
, 
<year box="[351,392,758,772]" pageId="19" pageNumber="20">2017</year>
. 
<title jopScore="0.09094897" pageId="19" pageNumber="20">Pharmacological and toxicological profile of harmane-β-carboline alkaloid: friend or foe</title>
. 
<journalOrPublisher box="[471,626,779,793]" jopScore="2.0600677" pageId="19" pageNumber="20">Curr. Drug Metabol.</journalOrPublisher>
<part box="[630,649,779,793]" pageId="19" pageNumber="20" type="volume">18</part>
(
<part box="[661,672,779,793]" pageId="19" pageNumber="20" type="issue">9</part>
), 
<pagination box="[688,756,779,793]" pageId="19" pageNumber="20" type="pagination">853–857</pagination>
. 
<DOI box="[132,563,800,814]" pageId="19" pageNumber="20">
https://doi.org/10.2174/ 
<uuid box="[313,563,800,814]" pageId="19" pageNumber="20">1389200218666170607100947</uuid>
</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8704" type="journal article">
<author box="[100,149,822,836]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Kirsch</author>
, 
<author box="[157,224,822,836]" case="TC" fns="I" in="E." ins="D" ln="Glenn" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Glenn E.</author>
, 
<author box="[231,294,822,836]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Fedorov</author>
, 
<author box="[303,380,822,836]" case="TC" fns="I" in="B." ins="D" ln="Nikolai" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Nikolai B.</author>
, 
<author box="[387,459,822,836]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Kuryshev</author>
, 
<author box="[467,524,822,836]" case="TC" fns="I" in="A." ins="D" ln="Yuri" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Yuri A.</author>
, 
<author box="[530,605,822,836]" case="TC" fn="Zhiqi" fnc="TC" fns="N" ln="Liu" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Liu, Zhiqi</author>
, 
<author box="[613,695,822,836]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Armstrong</author>
, 
<author box="[703,768,822,836]" case="TC" fns="I" in="C." ins="D" ln="Lucas" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Lucas C.</author>
, 
<author box="[132,160,843,857]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Orr</author>
, 
<author box="[168,250,843,857]" case="TC" fns="I" in="S." ins="D" ln="Michael" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Michael S.</author>
, 
<year box="[258,299,843,857]" pageId="19" pageNumber="20">2016</year>
. 
<title jopScore="0.11165275" pageId="19" pageNumber="20" type="_" typeScore="84">Electrophysiology-based assays to detect subtype-selective modulation of human nicotinic acetylcholine receptors. Assay Drug Dev</title>
. 
<journalOrPublisher box="[681,748,864,878]" jopScore="1.0" pageId="19" pageNumber="20">Technol.</journalOrPublisher>
<part box="[751,770,864,878]" pageId="19" pageNumber="20" type="volume">14</part>
(
<part box="[139,150,885,899]" pageId="19" pageNumber="20" type="issue">6</part>
), 
<pagination box="[165,233,885,899]" pageId="19" pageNumber="20" type="pagination">333–344</pagination>
. 
<DOI box="[241,533,885,900]" pageId="19" pageNumber="20">https://doi.org/10.1089/adt.2015.688</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8780" type="journal article">
<author box="[100,231,907,921]" case="TC" fns="I" in="N.H." ins="D" ln="Kleinsasser" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kleinsasser, N.H.</author>
, 
<author box="[239,342,907,921]" case="TC" fns="I" in="B.C." ins="D" ln="Wallner" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wallner, B.C.</author>
, 
<author box="[349,455,907,921]" case="TC" fns="I" in="U.A." ins="D" ln="Harreus" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Harréus, U.A.</author>
, 
<author box="[462,599,907,921]" case="TC" fns="I" in="W." ins="D" ln="Zwickenpflug" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Zwickenpflug, W.</author>
, 
<author box="[606,688,907,921]" case="TC" fns="I" in="E." ins="D" ln="Richter" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Richter, E.</author>
, 
<year box="[696,737,907,921]" pageId="19" pageNumber="20">2003</year>
. 
<title pageId="19" pageNumber="20">Genotoxic effects of myosmine in human lymphocytes and upper aerodigestive tract epithelial cells</title>
. 
<journalOrPublisher box="[252,335,949,963]" pageId="19" pageNumber="20">Toxicology</journalOrPublisher>
<part box="[340,370,949,963]" pageId="19" pageNumber="20" type="volume">192</part>
, 
<pagination box="[378,446,949,963]" pageId="19" pageNumber="20" type="pagination">171–177</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1016/S0300-483X(03) 00296-8</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8855" type="journal article">
<author box="[100,172,992,1006]" case="TC" fns="I" in="N.H." ins="D" ln="Lin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lin, N.H.</author>
, 
<author box="[179,284,992,1006]" case="TC" fns="I" in="C.M." ins="D" ln="Carrera" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Carrera, C.M.</author>
, 
<author box="[291,405,992,1006]" case="TC" fns="I" in="D.J." ins="D" ln="Anderson" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Anderson, D.J.</author>
, 
<year box="[413,454,992,1006]" pageId="19" pageNumber="20">1994</year>
. 
<title pageId="19" pageNumber="20">Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands</title>
. 
<journalOrPublisher box="[597,709,1013,1027]" pageId="19" pageNumber="20">J. Med. Chem.</journalOrPublisher>
<part box="[713,734,1013,1027]" pageId="19" pageNumber="20" type="volume">37</part>
, 
<pagination box="[132,219,1034,1048]" pageId="19" pageNumber="20" type="pagination">3542–3553</pagination>
. 
<DOI box="[228,524,1034,1048]" pageId="19" pageNumber="20">https://doi.org/10.1021/jm00047a012</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8917" type="journal article">
<author box="[100,169,1055,1069]" case="TC" fns="I" in="C.Y." ins="D" ln="Lin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lin, C.Y.</author>
, 
<author box="[176,253,1056,1070]" case="TC" fns="I" in="Z." ins="D" ln="Huang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Huang, Z.</author>
, 
<author box="[261,329,1056,1070]" case="TC" fns="I" in="W." ins="D" ln="Wen" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wen, W.</author>
, 
<author box="[336,391,1055,1070]" case="TC" fns="I" in="A." ins="D" ln="Wu" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wu, A.</author>
, 
<author box="[399,470,1055,1070]" case="TC" fns="I" in="C." ins="D" ln="Wang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wang, C.</author>
, 
<author box="[478,532,1055,1070]" case="TC" fns="I" in="L." ins="D" ln="Niu" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Niu, L.</author>
, 
<year box="[540,581,1055,1069]" pageId="19" pageNumber="20">2015</year>
. 
<title pageId="19" pageNumber="20">Enhancing protein expression in HEK-293 cells by lowering culture temperature</title>
. 
<journalOrPublisher box="[590,662,1077,1091]" pageId="19" pageNumber="20">PLoS One</journalOrPublisher>
<part box="[669,688,1077,1091]" pageId="19" pageNumber="20" type="volume">10</part>
(
<part box="[700,711,1077,1091]" pageId="19" pageNumber="20" type="issue">4</part>
), e 
<pagination box="[140,210,1098,1112]" pageId="19" pageNumber="20" type="pagination">0123562</pagination>
. 
<DOI box="[218,577,1098,1113]" pageId="19" pageNumber="20">https://doi.org/10.1371/journal.pone.0123562</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref8988" type="book">
<author box="[100,214,1119,1133]" case="TC" fns="I" in="P.M." ins="D" ln="Lippiello" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lippiello, P.M.</author>
, 
<author box="[221,335,1119,1133]" case="TC" fns="I" in="W.S." ins="D" ln="Caldwell" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Caldwell, W.S.</author>
, 
<year box="[342,383,1119,1133]" pageId="19" pageNumber="20">1993</year>
. 
<title pageId="19" pageNumber="20">Method for Treatment of Neurodegenerative Diseases</title>
. 
<journalOrPublisher box="[205,293,1140,1155]" pageId="19" pageNumber="20">USA Patent</journalOrPublisher>
, pp. 5242934.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9018" type="journal article">
<author box="[100,214,1162,1176]" case="TC" fns="I" in="P.M." ins="D" ln="Lippiello" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lippiello, P.M.</author>
, 
<author box="[221,326,1162,1176]" case="TC" fns="I" in="M." ins="D" ln="Bencherif" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Bencherif, M.</author>
, 
<author box="[334,447,1162,1176]" case="TC" fns="I" in="W.S." ins="D" ln="Caldwell" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Caldwell, W.S.</author>
, 
<author box="[454,570,1162,1176]" case="TC" fns="I" in="S.R." ins="D" ln="Arrington" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Arrington, S.R.</author>
, 
<author box="[578,680,1162,1176]" case="TC" fns="I" in="K.W." ins="D" ln="Fowler" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Fowler, K.W.</author>
, 
<author case="TC" fns="I" in="M.E." ins="D" ln="Lovette" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lovette, M.E.</author>
, 
<author box="[177,272,1183,1197]" case="TC" fns="I" in="L.K." ins="D" ln="Reeves" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Reeves, L.K.</author>
, 
<year box="[279,320,1183,1197]" pageId="19" pageNumber="20">1996</year>
. 
<title jopScore="0.07824463" pageId="19" pageNumber="20">Metanicotine: a nicotinic agonist with central nervous system selectivity-in vitro and in vivo characterization. Drug Dev</title>
. 
<journalOrPublisher box="[634,667,1204,1218]" jopScore="1.0754716" pageId="19" pageNumber="20">Res.</journalOrPublisher>
<part box="[670,691,1204,1218]" pageId="19" pageNumber="20" type="volume">38</part>
, 
<pagination box="[699,767,1204,1218]" pageId="19" pageNumber="20" type="pagination">169–176</pagination>
. 
<DOI box="[132,761,1225,1240]" pageId="19" pageNumber="20">https://doi.org/10.1002/(SICI)1098-2299(199607/08)38:3/4&lt;169::AID-DDR5&gt;3</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" box="[132,212,1247,1261]" pageId="19" pageNumber="20">0.CO. 2-K.</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" author="Macnicol, P. K." journalOrPublisher="Biochem. J." pageId="19" pageNumber="20" part="5665251" refId="ref9135" title="Isolation for 6 - hydroxykynurenic acid from the tobacco leaf" type="journal volume" year="1968">
<author box="[100,213,1268,1282]" case="TC" fns="I" in="P.K." ins="D" ln="Macnicol" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Macnicol, P.K.</author>
, 
<year box="[220,261,1268,1282]" pageId="19" pageNumber="20">1968</year>
. 
<title box="[268,726,1268,1282]" pageId="19" pageNumber="20">Isolation for 6-hydroxykynurenic acid from the tobacco leaf</title>
. 
<journalOrPublisher box="[132,222,1289,1304]" pageId="19" pageNumber="20">Biochem. J.</journalOrPublisher>
473–479 PMID: 
<part box="[351,418,1289,1303]" pageId="19" pageNumber="20" type="volume">5665251</part>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9166" type="journal article">
<author box="[100,221,1310,1325]" case="TC" fns="I" in="A.H." ins="D" ln="Malkawia" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Malkawia, A.H.</author>
, 
<author box="[228,398,1310,1325]" case="TC" fns="I" in="A.M." ins="D" ln="Al-Ghananeema" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Al-Ghananeema, A.M.</author>
, 
<author box="[405,470,1310,1325]" case="TC" fns="I" in="Jd" ins="U" ln="Leon" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Leon, Jd</author>
, 
<author box="[480,576,1310,1325]" case="TC" fns="I" in="P.A." ins="D" ln="Crooks" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Crooks, P.A.</author>
, 
<year box="[583,624,1310,1324]" pageId="19" pageNumber="20">2008</year>
. 
<title pageId="19" pageNumber="20">Nicotine exposure can be detected in cerebrospinal fluid of active</title>
. 
<journalOrPublisher box="[501,688,1332,1346]" pageId="19" pageNumber="20">J. Pharm. Biomed. Anal.</journalOrPublisher>
<part box="[692,722,1332,1346]" pageId="19" pageNumber="20" type="volume">129</part>
, 
<pagination box="[731,762,1332,1346]" pageId="19" pageNumber="20" type="pagination">132</pagination>
. 
<DOI box="[132,466,1353,1367]" pageId="19" pageNumber="20">https://doi.org/10.1016/j.jpba.2008.10.003</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9231" type="journal article">
<author box="[100,213,1374,1389]" case="TC" fns="I" in="A.A." ins="D" ln="Mazurov" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Mazurov, A.A.</author>
, 
<author box="[220,315,1374,1389]" case="TC" fns="I" in="J.D." ins="D" ln="Speake" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Speake, J.D.</author>
, 
<author box="[323,425,1374,1389]" case="TC" fns="I" in="D." ins="D" ln="Yohannes" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Yohannes, D.</author>
, 
<year box="[433,474,1374,1388]" pageId="19" pageNumber="20">2011</year>
. 
<title pageId="19" pageNumber="20">Discovery and development of α7 nicotinic acetylcholine receptor modulators</title>
. 
<journalOrPublisher box="[458,570,1395,1410]" pageId="19" pageNumber="20">J. Med. Chem.</journalOrPublisher>
<part box="[573,594,1395,1409]" pageId="19" pageNumber="20" type="volume">54</part>
, 
<pagination box="[603,690,1395,1409]" pageId="19" pageNumber="20" type="pagination">7943–7961</pagination>
. 
<DOI pageId="19" pageNumber="20">https:// doi.org/10.1021/jm2007672</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[100,771,163,1538]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9287" type="journal article">
<author box="[100,212,1438,1452]" case="TC" fns="I" in="A.A." ins="D" ln="Mazurov" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Mazurov, A.A.</author>
, 
<author box="[218,283,1438,1452]" case="TC" fns="I" in="L." ins="D" ln="Miao" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Miao, L.</author>
, 
<author box="[289,375,1438,1452]" case="TC" fns="I" in="B.S." ins="D" ln="Bhatti" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Bhatti, B.S.</author>
, 
<author box="[382,488,1438,1452]" case="TC" fns="I" in="J.P." ins="D" ln="Strachan" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Strachan, J.P.</author>
, 
<author box="[495,589,1438,1452]" case="TC" fns="I" in="S." ins="D" ln="Akireddy" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Akireddy, S.</author>
, 
<author box="[597,678,1438,1452]" case="TC" fns="I" in="S." ins="D" ln="Murthy" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Murthy, S.</author>
, 
<author box="[686,768,1438,1452]" case="TC" fns="I" in="D." ins="D" ln="Kombo" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kombo, D.</author>
, et al., 
<year box="[181,222,1459,1473]" pageId="19" pageNumber="20">2012</year>
. 
<title jopScore="0.25338426" pageId="19" pageNumber="20">Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders</title>
. 
<journalOrPublisher box="[502,614,1502,1516]" jopScore="0.375" pageId="19" pageNumber="20">J. Med. Chem.</journalOrPublisher>
<part box="[618,639,1502,1516]" pageId="19" pageNumber="20" type="volume">55</part>
, 
<pagination box="[647,734,1502,1516]" pageId="19" pageNumber="20" type="pagination">9181–9194</pagination>
. 
<DOI box="[132,410,1523,1538]" pageId="19" pageNumber="20">https://doi.org/10.1021/jm3006542</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9405" type="book chapter">
<author box="[818,901,163,177]" case="TC" fns="I" in="E.I." ins="D" ln="Miller" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Miller, E.I.</author>
, 
<author box="[908,991,163,177]" case="TC" fns="I" in="HR" ins="B" ln="Norris" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Norris, HR</author>
, 
<author box="[999,1085,163,177]" case="TC" fns="I" in="DE" ins="B" ln="Rollins" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Rollins, DE</author>
, 
<author box="[1093,1188,163,177]" case="TC" fns="I" in="S.T." ins="D" ln="Tiffany" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Tiffany, S.T.</author>
, 
<author box="[1195,1298,163,177]" case="TC" fns="I" in="D.G." ins="D" ln="Wilkins" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wilkins, D.G.</author>
, 
<year box="[1305,1346,163,177]" pageId="19" pageNumber="20">2009</year>
. 
<title jopScore="0.13201627" pageId="19" pageNumber="20">A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometr. J Chromatogr</title>
. 
<journalOrPublisher box="[949,1203,248,262]" jopScore="1.2859757" pageId="19" pageNumber="20">B Anal. Technol. Biomed. Life Sci</journalOrPublisher>
. 
<pagination box="[1210,1278,248,262]" pageId="19" pageNumber="20" type="pagination">725–737</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1016/j. jchromb.2009.12.018</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9502" type="book chapter">
<author pageId="19" pageNumber="20">Mishra, Aseem, Chaturvedi, Pankaj, Datta, Sourav, Sinukumar, Snita, Joshi, Poonam, Garg, Apurva</author>
, 
<year box="[961,1002,311,325]" pageId="19" pageNumber="20">2015</year>
. 
<title box="[1010,1216,312,326]" jopScore="0.06554598" pageId="19" pageNumber="20" type="_" typeScore="58">Harmful effects of nicotine</title>
. 
<journalOrPublisher box="[1224,1460,312,326]" jopScore="0.77523947" pageId="19" pageNumber="20">Indian J. Med. Paediatr. Oncol</journalOrPublisher>
. 
<pagination box="[849,898,333,347]" pageId="19" pageNumber="20" type="pagination">24–31</pagination>
. 
<DOI box="[907,1243,333,348]" pageId="19" pageNumber="20">https://doi.org/10.4103/0971-5851.151771</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9559" type="journal article">
<author box="[818,906,354,368]" case="TC" fns="I" in="R.T." ins="D" ln="Owen" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Owen, R.T.</author>
, 
<author box="[913,1011,354,368]" case="TC" fns="I" in="N." ins="D" ln="Serradell" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Serradell, N.</author>
, 
<author box="[1018,1082,354,368]" case="TC" fns="I" in="E." ins="D" ln="Rosa" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Rosa, E.</author>
, 
<year box="[1089,1130,354,368]" pageId="19" pageNumber="20">2008</year>
. 
<title pageId="19" pageNumber="20">Ispronicline: nicotinic acetylcholine α4β2 agonist treatment of cognition disorders</title>
. 
<journalOrPublisher box="[1163,1261,376,390]" pageId="19" pageNumber="20">Drugs Future</journalOrPublisher>
<part box="[1266,1285,375,389]" pageId="19" pageNumber="20" type="volume">33</part>
(
<part box="[1298,1308,375,389]" pageId="19" pageNumber="20" type="issue">3</part>
), 
<pagination box="[1323,1392,375,389]" pageId="19" pageNumber="20" type="pagination">197–202</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi. org/10.1358/dof.2008.033.03.1184544</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9616" type="journal article">
<author box="[818,906,418,432]" case="TC" fns="I" in="R.L." ins="D" ln="Papke" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Papke, R.L.</author>
, 
<author box="[913,1053,418,432]" case="TC" fns="I" in="J.K." ins="D" ln="Porter Papke" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Porter Papke, J.K.</author>
, 
<year box="[1061,1102,418,432]" pageId="19" pageNumber="20">2002</year>
. 
<title pageId="19" pageNumber="20">Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis</title>
. 
<journalOrPublisher box="[1178,1307,439,453]" pageId="19" pageNumber="20">Br. J. Pharmacol.</journalOrPublisher>
<part box="[1310,1331,439,453]" pageId="19" pageNumber="20" type="volume">49</part>
, 
<pagination box="[1338,1359,439,453]" pageId="19" pageNumber="20" type="pagination">61</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/ 10.1038/sj.bjp.0704833</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9673" type="journal article">
<author box="[818,865,481,495]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Papke</author>
, 
<author box="[873,940,482,496]" case="TC" fns="I" in="L." ins="D" ln="Roger" lnc="TC" npo="LnIn" pageId="19" pageNumber="20">Roger L.</author>
, Smith-Maxwell, Cathy, 
<year box="[1126,1167,482,496]" pageId="19" pageNumber="20">2009</year>
. 
<title jopScore="0.0017857144" pageId="19" pageNumber="20" type="_" typeScore="84">High-throughput electrophysiology with Xenopus oocytes</title>
. 
<journalOrPublisher box="[984,1283,503,517]" jopScore="0.15" pageId="19" pageNumber="20">Comb. Chem. High Throughput Screen.</journalOrPublisher>
<part box="[1286,1305,503,517]" pageId="19" pageNumber="20" type="volume">12</part>
(
<part box="[1318,1326,503,517]" pageId="19" pageNumber="20" type="issue">1</part>
), 
<pagination box="[1343,1392,503,517]" pageId="19" pageNumber="20" type="pagination">38–50</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi. org/10.2174/138620709787047975</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9719" type="journal article">
<author box="[818,893,545,560]" case="TC" fns="I" in="A." ins="D" ln="Potter" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Potter, A.</author>
, 
<author box="[900,980,545,560]" case="TC" fns="I" in="J." ins="D" ln="Corwin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Corwin, J.</author>
, 
<author box="[989,1050,546,560]" case="TC" fns="I" in="J." ins="D" ln="Lang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lang, J.</author>
, 
<author box="[1059,1153,545,560]" case="TC" fns="I" in="M." ins="D" ln="Piasecki" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Piasecki, M.</author>
, 
<author box="[1160,1234,546,560]" case="TC" fns="I" in="R." ins="D" ln="Lenox" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lenox, R.</author>
, 
<author box="[1242,1364,545,559]" case="TC" fns="I" in="P.A." ins="D" ln="Newhouse" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Newhouse, P.A.</author>
, 
<year box="[1371,1412,545,559]" pageId="19" pageNumber="20">1999</year>
. 
<title pageId="19" pageNumber="20">
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT- 
<quantity box="[1434,1481,567,581]" metricMagnitude="1" metricUnit="m" metricValue="1.06172" pageId="19" pageNumber="20" unit="in" value="418.0">418 in</quantity>
Alzheimer's disease
</title>
. 
<journalOrPublisher box="[1006,1166,588,602]" pageId="19" pageNumber="20">Psychopharmacology</journalOrPublisher>
<part box="[1171,1200,588,602]" pageId="19" pageNumber="20" type="volume">142</part>
(
<part box="[1212,1223,588,602]" pageId="19" pageNumber="20" type="issue">4</part>
), 
<pagination box="[1238,1307,588,602]" pageId="19" pageNumber="20" type="pagination">334–342</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10. 1007/s002130050897</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9795" type="journal article">
<title jopScore="2.3702197" pageId="19" pageNumber="20" type="_" typeScore="12">
<author box="[818,949,630,645]" case="TC" fn="Renza" fnc="TC" fns="N" ln="Roncarati" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Roncarati, Renza</author>
, 
<author box="[957,1109,630,645]" case="TC" fn="Tamara" fnc="TC" fns="N" ln="Seredenina" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Seredenina, Tamara</author>
, 
<author box="[1118,1201,630,645]" case="TC" fn="Brian" fnc="TC" fns="N" ln="Jow" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Jow, Brian</author>
, 
<author box="[1210,1292,630,645]" case="TC" fn="Flora" fnc="TC" fns="N" ln="Jow" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Jow, Flora</author>
, 
<author box="[1300,1403,630,644]" case="TC" fn="Silvia" fnc="TC" fns="N" ln="Papini" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Papini, Silvia</author>
, 
<author case="TC" fn="Angela" fnc="TC" fns="N" ln="Kramer" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kramer, Angela</author>
, 
<author box="[911,1069,652,666]" case="TC" fn="Hendrick" fnc="TC" fns="N" ln="Bothmann" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Bothmann, Hendrick</author>
, 
<author box="[1076,1180,652,666]" case="TC" fn="John" fnc="TC" fns="N" ln="Dunlop" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Dunlop, John</author>
</title>
, 
<author box="[1187,1260,652,666]" case="TC" fns="I" in="C." ins="D" ln="Georg" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Georg, C.</author>
, Terstappen, 
<year box="[1359,1400,652,666]" pageId="19" pageNumber="20">2008</year>
. 
<journalOrPublisher jopScore="0.10460848" pageId="19" pageNumber="20">Functional properties of α</journalOrPublisher>
<part box="[961,970,673,687]" pageId="19" pageNumber="20" type="volume">7</part>
nicotinic acetylcholine receptors Co-expressed with RIC- 
<quantity box="[1399,1426,673,687]" metricMagnitude="-2" metricUnit="m" metricValue="7.62" pageId="19" pageNumber="20" unit="in" value="3.0">
<pagination box="[1399,1406,673,687]" pageId="19" pageNumber="20" type="pagination">3</pagination>
in
</quantity>
a stable recombinant CHO-K1 cell line. Assay Drug Dev. Technol. 6 (2). 
<DOI pageId="19" pageNumber="20">https://doi.org/10. 1089/adt.2007.120</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9883" type="journal article">
<author box="[818,910,737,751]" case="TC" fns="I" in="L.E." ins="D" ln="Rueter" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Rueter, L.E.</author>
, 
<author box="[917,1031,737,751]" case="TC" fns="I" in="D.J." ins="D" ln="Anderson" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Anderson, D.J.</author>
, 
<author box="[1038,1131,737,751]" case="TC" fns="I" in="C.A." ins="D" ln="Birggs" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Birggs, C.A.</author>
, 
<author box="[1138,1312,737,751]" case="TC" fns="I" in="D.L." ins="D" ln="Donnelly-Roberts" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Donnelly-Roberts, D.L.</author>
, 
<author box="[1319,1422,737,751]" case="TC" fns="I" in="G.A." ins="D" ln="Gintant" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Gintant, G.A.</author>
, 
<author box="[849,1000,758,772]" case="TC" fns="I" in="M." ins="D" ln="Gopalakrishnan" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Gopalakrishnan, M.</author>
, 
<author box="[1005,1076,758,772]" case="TC" fns="I" in="N.H." ins="D" ln="Lin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Lin, N.H.</author>
, et al., 
<year box="[1128,1169,758,772]" pageId="19" pageNumber="20">2004</year>
. 
<title pageId="19" pageNumber="20">ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders</title>
. 
<journalOrPublisher box="[1004,1119,800,815]" pageId="19" pageNumber="20">CNS Drug Rev.</journalOrPublisher>
<part box="[1122,1141,800,814]" pageId="19" pageNumber="20" type="volume">10</part>
(
<part box="[1154,1165,800,814]" pageId="19" pageNumber="20" type="issue">2</part>
), 
<pagination box="[1180,1248,800,814]" pageId="19" pageNumber="20" type="pagination">167–182</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1111/j. 1527-3458.2004.tb00011.x</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref9989" type="journal article">
<author box="[818,892,843,857]" case="TC" fns="I" in="F." ins="D" ln="Saitoh" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Saitoh, F.</author>
, 
<author box="[900,973,843,857]" case="TC" fns="I" in="M." ins="D" ln="Nona" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Nona, M.</author>
, 
<author box="[980,1097,843,857]" case="TC" fns="I" in="N." ins="D" ln="Kawashima" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kawashima, N.</author>
, 
<year box="[1104,1145,843,857]" pageId="19" pageNumber="20">1985</year>
. 
<title pageId="19" pageNumber="20">The alkaloid contents of sixty Nicotiana species</title>
. 
<journalOrPublisher box="[913,1030,864,878]" pageId="19" pageNumber="20">Phytochemistry</journalOrPublisher>
<part box="[1036,1057,864,878]" pageId="19" pageNumber="20" type="volume">24</part>
, 
<pagination box="[1065,1133,864,878]" pageId="19" pageNumber="20" type="pagination">477–480</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1016/S0031-9422(00) 80751-7</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10041" type="journal article">
<author box="[818,931,907,921]" case="TC" fns="I" in="N.S." ins="D" ln="Sapronov" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Sapronov, N.S.</author>
, 
<author box="[938,1074,907,921]" case="TC" fns="I" in="L.K." ins="D" ln="Khnychenko" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Khnychenko, L.K.</author>
, 
<year box="[1080,1121,907,921]" pageId="19" pageNumber="20">1982</year>
. 
<title jopScore="0.06281786" pageId="19" pageNumber="20">Pharmacology of the Anabasis aphylla alkaloids anabasine and anabasamine</title>
. 
<journalOrPublisher box="[1072,1294,928,942]" jopScore="0.0041878573" pageId="19" pageNumber="20">Farmakologiia i toksikologiia</journalOrPublisher>
<part box="[1299,1318,928,942]" pageId="19" pageNumber="20" type="volume">45</part>
(
<part box="[1330,1341,928,942]" pageId="19" pageNumber="20" type="issue">6</part>
), 
<pagination box="[1357,1403,928,942]" pageId="19" pageNumber="20" type="pagination">25–27</pagination>
PMID: 7151996.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10082" type="journal article">
<author box="[818,949,970,984]" case="TC" fn="Corinna" fnc="TC" fns="N" ln="Scheffel" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Scheffel, Corinna</author>
, 
<author box="[957,1060,970,985]" case="TC" fns="I" in="K.V." ins="D" ln="Niessen" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Niessen, K.V.</author>
, 
<author box="[1067,1191,970,984]" case="TC" fns="I" in="S." ins="D" ln="Rappengluck" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Rappenglück, S.</author>
, 
<author box="[1199,1302,971,985]" case="TC" fns="I" in="K.T." ins="D" ln="Wanner" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wanner, K.T.</author>
, 
<author box="[1309,1422,970,985]" case="TC" fns="I" in="H." ins="D" ln="Thiermann" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Thiermann, H.</author>
, 
<author case="TC" fns="I" in="F." ins="D" ln="Worek" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Worek, F.</author>
, 
<author box="[874,951,992,1006]" case="TC" fns="I" in="T." ins="D" ln="Seeger" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Seeger, T.</author>
, 
<year box="[959,1000,992,1006]" pageId="19" pageNumber="20">2018</year>
. 
<title jopScore="0.09657411" pageId="19" pageNumber="20" type="_" typeScore="84">Counteracting desensitization of human α7-nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning</title>
. 
<journalOrPublisher box="[1023,1123,1034,1049]" jopScore="0.5" pageId="19" pageNumber="20">Toxicol. Lett.</journalOrPublisher>
<part box="[1126,1156,1034,1048]" pageId="19" pageNumber="20" type="volume">293</part>
, 
<pagination box="[1163,1232,1034,1048]" pageId="19" pageNumber="20" type="pagination">149–156</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1016/j.toxlet. 2017.12.005</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10169" type="journal article">
<author box="[818,927,1077,1091]" case="TC" fns="I" in="A K" ins="U" ln="Steppuhn" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Steppuhn, A K</author>
<author box="[933,971,1077,1091]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Gase</author>
, 
<author box="[979,1051,1077,1091]" case="TC" fns="I" in="B." ins="D" ln="Krock" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Krock, B.</author>
, 
<author box="[1058,1167,1077,1091]" case="TC" fns="I" in="R." ins="D" ln="Halitschke" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Halitschke, R.</author>
, 
<author box="[1174,1274,1077,1091]" case="TC" fns="I" in="I.T." ins="D" ln="Baldwin" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Baldwin, I.T.</author>
, 
<year box="[1282,1323,1077,1091]" pageId="19" pageNumber="20">2004</year>
. 
<title pageId="19" pageNumber="20">Nicotine's defensive function in nature</title>
. 
<journalOrPublisher box="[997,1076,1098,1112]" pageId="19" pageNumber="20">PLoS Biol.</journalOrPublisher>
<part box="[1080,1091,1098,1112]" pageId="19" pageNumber="20" type="volume">2</part>
, 
<pagination box="[1100,1188,1098,1112]" pageId="19" pageNumber="20" type="pagination">1074–1080</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10.1371/journal.pbio. 0020217</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10224" type="journal article">
<author box="[818,931,1140,1155]" case="TC" fn="Jing-shu" fnc="TC" fns="N" ln="Tang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Tang, Jing-shu</author>
, 
<author box="[939,1042,1140,1154]" case="TC" fn="Bing-xue" fnc="TC" fns="N" ln="Xie" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Xie, Bing-xue</author>
, 
<author box="[1051,1147,1140,1154]" case="TC" fn="Xi-ling" fnc="TC" fns="N" ln="Bian" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Bian, Xi-ling</author>
, 
<author box="[1155,1217,1141,1155]" case="TC" fns="I" in="Yu" ins="U" ln="Xue" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Xue, Yu</author>
, 
<author box="[1225,1342,1140,1154]" case="TC" fn="Ning-ning" fnc="TC" fns="N" ln="Wei" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wei, Ning-ning</author>
, 
<author box="[1350,1475,1140,1154]" case="TC" fn="Jing-heng" fnc="TC" fns="N" ln="Zhou" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Zhou, Jing-heng</author>
, 
<author box="[849,913,1162,1176]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Yu-chen</author>
, 
<author box="[921,977,1162,1176]" case="TC" fns="I" in="Li" ins="U" ln="Hao" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Hao, Li</author>
, Gang, Zhang, Liang-ren, Wang, Ke-wei, 
<year box="[1285,1326,1162,1176]" pageId="19" pageNumber="20">2015</year>
. 
<title jopScore="0.12294614" pageId="19" pageNumber="20" type="_" typeScore="84">Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B</title>
. 
<journalOrPublisher box="[1134,1292,1204,1218]" jopScore="2.7797618" pageId="19" pageNumber="20">Acta Pharmacol. Sin.</journalOrPublisher>
<part box="[1295,1316,1204,1218]" pageId="19" pageNumber="20" type="volume">36</part>
, 
<pagination box="[1324,1392,1204,1218]" pageId="19" pageNumber="20" type="pagination">800–812</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi. org/10.1038/aps.2015.9</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" author="Tsuzaki, Y. &amp; Ito, A. &amp; Kiuchi, K." pageId="19" pageNumber="20" refId="ref10312" title="Lumichrome Derivatives as Inhibitors for Cancer Metastasis" type="book" year="1994">
<author box="[818,904,1247,1261]" case="TC" fns="I" in="Y." ins="D" ln="Tsuzaki" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Tsuzaki, Y.</author>
, 
<author box="[911,962,1247,1261]" case="TC" fns="I" in="A." ins="D" ln="Ito" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Ito, A.</author>
, 
<author box="[969,1047,1247,1261]" case="TC" fns="I" in="K." ins="D" ln="Kiuchi" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kiuchi, K.</author>
, 
<year box="[1054,1095,1247,1261]" pageId="19" pageNumber="20">1994</year>
. 
<title pageId="19" pageNumber="20">Lumichrome Derivatives as Inhibitors for Cancer Metastasis</title>
., 06279445 Japan Patent.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10342" type="book chapter">
<author box="[818,899,1289,1304]" case="TC" fns="I" in="M." ins="D" ln="Weber" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Weber, M.</author>
, 
<author box="[907,997,1289,1304]" case="TC" fns="I" in="D." ins="D" ln="Dietrich" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Dietrich, D.</author>
, 
<author box="[1005,1075,1289,1304]" case="TC" fns="I" in="I." ins="D" ln="Grasel" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Gräsel, I.</author>
, 
<author box="[1083,1163,1289,1304]" case="TC" fns="I" in="G." ins="D" ln="Reuter" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Reuter, G.</author>
, 
<author box="[1170,1249,1289,1303]" case="TC" fns="I" in="G." ins="D" ln="Seifert" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Seifert, G.</author>
, 
<author box="[1256,1373,1289,1303]" case="TC" fns="I" in="C." ins="D" ln="Steinhauser" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Steinhäuser, C.</author>
, 
<year box="[1380,1421,1289,1303]" pageId="19" pageNumber="20">2001</year>
. 6- 
<title jopScore="0.031442378" pageId="19" pageNumber="20">Hydroxykynurenic acid and kynurenic acid differently antagonise AMPA and NMDA receptors in hippocampal neurones. J</title>
. 
<journalOrPublisher box="[1145,1234,1332,1346]" jopScore="0.0018495516" pageId="19" pageNumber="20">Neurochem</journalOrPublisher>
. 
<pagination box="[1242,1329,1332,1346]" pageId="19" pageNumber="20" type="pagination">1108–1115</pagination>
. 
<DOI pageId="19" pageNumber="20">https://doi.org/10. 1046/j.1471-4159.2001.00340.x</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10418" type="book chapter">
<author box="[818,877,1374,1389]" case="TC" fn="Jie" fnc="TC" fns="N" ln="Wu" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Wu, Jie</author>
, 
<author box="[886,912,1374,1388]" fns="*" inm="true" npo="*" pageId="19" pageNumber="20">Liu</author>
, 
<author box="[920,997,1374,1389]" case="TC" fns="I" in="Yu" ins="U" ln="Qiang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Qiang, Yu</author>
, 
<author box="[1006,1086,1374,1389]" case="TC" fns="I" in="Hu" ins="U" ln="Kewei" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Kewei, Hu</author>
, 
<author box="[1095,1165,1375,1389]" case="TC" fn="Kuo" fnc="TC" fns="N" ln="Jun" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Jun, Kuo</author>
, 
<author box="[1173,1328,1374,1388]" case="TC" fn="Segerberg" fnc="TC" fns="N" ln="Yen-Ping" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Yen-Ping, Segerberg</author>
, 
<author box="[1336,1452,1374,1388]" case="TC" fn="Paul A" fns="N" ln="Marsha" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Marsha, Paul A</author>
<author case="TC" fns="I" in="J" ins="U" ln="St John" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">St John, J</author>
Lukas, Ronald, 
<year box="[1028,1069,1395,1409]" pageId="19" pageNumber="20">2006</year>
. 
<title jopScore="0.09242753" pageId="19" pageNumber="20" type="_" typeScore="58">Roles of nicotinic acetylcholine receptor βsubunits in function of human α4-containing nicotinic receptors</title>
. 
<journalOrPublisher box="[1258,1334,1417,1431]" jopScore="0.4" pageId="19" pageNumber="20">J. Physiol</journalOrPublisher>
. 
<pagination box="[1342,1411,1417,1431]" pageId="19" pageNumber="20" type="pagination">103–118</pagination>
. 
<DOI pageId="19" pageNumber="20">https:// doi.org/10.1113/jphysiol.2006.114645</DOI>
.
</bibRef>
</paragraph>
<paragraph blockId="19.[818,1489,163,1516]" pageId="19" pageNumber="20">
<bibRef _evidence="authorList" pageId="19" pageNumber="20" refId="ref10492" type="book chapter">
<author box="[818,909,1459,1473]" case="TC" fn="Taoyi" fnc="TC" fns="N" ln="Yang" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Yang, Taoyi</author>
, 
<author box="[917,997,1459,1473]" case="TC" fn="Ting" fnc="TC" fns="N" ln="Xiao" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Xiao, Ting</author>
, 
<author box="[1005,1063,1459,1473]" case="TC" fns="I" in="Qi" ins="U" ln="Sun" lnc="TC" npo="LnFn" pageId="19" pageNumber="20">Sun, Qi</author>
, Wanga, Kewei, 
<year box="[1188,1229,1459,1473]" pageId="19" pageNumber="20">2017</year>
. 
<title jopScore="0.0691467" pageId="19" pageNumber="20" type="_" typeScore="58">The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials</title>
. 
<journalOrPublisher jopScore="2.885277" pageId="19" pageNumber="20">Acta Pharm. Sin. B</journalOrPublisher>
<pagination box="[900,968,1502,1516]" pageId="19" pageNumber="20" type="pagination">611–622</pagination>
. 
<DOI box="[976,1312,1502,1516]" pageId="19" pageNumber="20">https://doi.org/10.1016/j.apsb.2017.09.001</DOI>
.
</bibRef>
</paragraph>
</subSection>
</document>